var title_f32_18_33056="Clotrimazole: Drug information";
var content_f32_18_33056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clotrimazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35780?source=see_link\">",
"       Clotrimazole (oral): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/61/29652?source=see_link\">",
"       Clotrimazole (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9287 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-93FDCDF71C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33056=[""].join("\n");
var outline_f32_18_33056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35780?source=related_link\">",
"      Clotrimazole (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/61/29652?source=related_link\">",
"      Clotrimazole (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33057="Oxychlorosene: Drug information";
var content_f32_18_33057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxychlorosene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/53/20307?source=see_link\">",
"    see \"Oxychlorosene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clorpactin&reg; WCS-90 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local infections: Topical (0.1% to 0.5% solutions): Apply by irrigation, instillation, spray, soaks, or wet compresses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, topical, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clorpactin&reg; WCS-90: 2 g/bottle",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of localized infections",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxychlorosene or any component of the formulation; site of infection not exposed to direct contact with the solution",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Clorpactin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (2 g): $5.74",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10183 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33057=[""].join("\n");
var outline_f32_18_33057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204852\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204857\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204853\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204854\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204846\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204838\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204847\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204849\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299803\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222057\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323569\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10183|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/53/20307?source=related_link\">",
"      Oxychlorosene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33058="CDC weight for age girls 0 to 36 months";
var content_f32_18_33058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls, birth to 36 months, CDC growth charts: United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 658px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33058=[""].join("\n");
var outline_f32_18_33058=null;
var title_f32_18_33059="Cystic hygroma CXR IV";
var content_f32_18_33059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma infiltrating lung in adult patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows an anterior mediastinal mass with involvement of the adjacent left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33059=[""].join("\n");
var outline_f32_18_33059=null;
var title_f32_18_33060="Verteporfin: Drug information";
var content_f32_18_33060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Verteporfin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/3/6196?source=see_link\">",
"    see \"Verteporfin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13164018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Visudyne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Visudyne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapy is a two-step process; first the infusion of verteporfin, then the activation of verteporfin with a nonthermal diode laser (for light administration details, see Administration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Subfoveal choroidal neovascularization:",
"     </b>",
"     I.V.: 6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     body surface area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment in more than one eye: Patients who have lesions in both eyes should be evaluated and treatment should first be done to the more aggressive lesion. Following safe and acceptable treatment, the second eye can be treated one week later. Patients who have had previous verteporfin therapy, with an acceptable safety profile, may then have both eyes treated concurrently. Treat the more aggressive lesion followed immediately with the second eye. The light treatment to the second eye should begin no later than 20 minutes from the start of the infusion.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Patients &ge;75 years were less likely to benefit from therapy in clinical trials.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13913733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, half-life is increased by 20% with mild hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe impairment: Use caution; no dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Visudyne&reg;: 15 mg [contains egg phosphatidylglycerol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A free-flowing I.V. line should be established prior to starting infusion.  Use of the largest arm vein, especially in the elderly, is suggested; avoid small veins in the back of the hand. Reconstituted solution should be given at 3 mL/minute over 10 minutes using a syringe pump and an in-line filter.   If extravasation occurs (see Extravasation management), protect the site from light.  Use of rubber gloves and eye protection is recommended. Skin and eye contact should be avoided and all materials should be disposed of properly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     Stop infusion. To decrease the chance of a severe burn, protect the area of extravasation from direct light until swelling and discoloration have faded. Apply cold compresses to the injection site.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Light administration: Following intravenous infusion, verteporfin must be light activated using a nonthermal diode laser. The system must provide a stable power output at a wavelength of 689 &plusmn; 3 nm. Approved laser systems are listed in manufacturer's package insert. Light delivery should begin 15 minutes following the start of the 10-minute infusion. The light dose is 50 J/cm",
"     <sup>",
"      2",
"     </sup>",
"     of neovascular lesion administered over 83 seconds at an intensity of 600 mW/cm",
"     <sup>",
"      2",
"     </sup>",
"     . Instructions for determining lesion size and treatment spot size can also be found in the package insert.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, presumed ocular histoplasmosis, or pathologic myopia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F233971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Predominantly",
"     <b>",
"      occult",
"     </b>",
"     subfoveal choroidal neovascularization",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (including injection site discoloration, edema, extravasation, hemorrhage, inflammation, pain, and rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, flashes of light, visual acuity decreased, visual field defects (including scotoma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, hypertension, peripheral vascular disorder, varicose veins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever, hypoesthesia, sleep disturbance, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Eczema, photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, gastrointestinal cancers, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Prostatic disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, leukocytosis, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthrosis, back pain (primarily during infusion), myasthenia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia, lacrimation disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment site: Blepharitis, cataracts, conjunctivitis/conjunctival injection, dry eyes, ocular itching, severe vision loss with or without subretinal/retinal or vitreous hemorrhage (decrease in 4 lines or more within 7 days of treatment [1% to 5%])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Albuminuria, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Frequency not defined or &lt;1% (limited to important or life-threatening): Chest pain, hypersensitivity reaction, musculoskeletal pain (during infusion), retinal detachment (nonrhegmatogenous), retinal or choroidal vessel nonperfusion, retinal pigment epithelial tear, vasovagal reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to verteporfin or any component of the formulation; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions: Chest pain, vasovagal and hypersensitivity reactions have occurred rarely; observation of patient during infusion is suggested.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Avoid exposing skin or eyes to direct sunlight or bright indoor light for 5 days following treatment; in case of emergency surgery within 48 hours of treatment, protect as much of the internal tissue as possible from intense light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary obstruction: Use with caution in patients with biliary obstruction; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with moderate-to-severe hepatic impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anesthesia: Use with caution in patients under anesthesia; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Patients &ge;75 years of age are less likely to benefit from therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not retreat patients who experience a decrease of vision &ge;4 lines within 1 week of treatment unless vision recovers and the potential benefits and risks are carefully considered. Use of incompatible lasers (which do not provide the required light for photoactivation) can result in incomplete treatment, overtreatment, or damage to normal tissue. Patients with dark irides, occult lesions,  or &lt;50% classic choroidal neovascularization are less likely to benefit from therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Concurrent administration in both eyes: Use in more than one eye has not been studied; however, it is recommended that if required, initial treatment should be applied to the more aggressive lesion first, followed by the second eye a week later (subsequent treatment may be concurrent).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Standard precautions should be taken to avoid extravasation (eg free-flowing I.V. line, use of largest arm vein). If extravasation occurs, stop the infusion immediately and protect from direct light until swelling and discoloration have faded; use cold compresses and oral pain medications, if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Safety and efficacy have not been established of use for longer than 2 years.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F233953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Ethanol may decrease efficacy of verteporfin.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F518319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Verteporfin and its metabolite were in the breast milk of one woman; milk levels were 66% of plasma levels following infusion; the metabolite was still detected 48 hours later.  The manufacturer recommends that nursing be discontinued or treatment be postponed.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Visudyne Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (1): $1858.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intravenous site during infusion, to avoid extravasation; fluorescein angiography every 3 months to monitor choroidal neovascular leakage (if detected, repeat therapy)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Visudine (GR);",
"     </li>",
"     <li>",
"      Visudyne (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, HK, HN, ID, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PE, PH, PK, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following intravenous administration, verteporfin is transported by lipoproteins to the neovascular endothelium in the affected eye(s), including choroidal neovasculature and the retina. Verteporfin then needs to be activated by nonthermal red light, which results in local damage to the endothelium, leading to temporary choroidal vessel occlusion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and by plasma esterases to diacid metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 5-6 hours, biexponential",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10032 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33060=[""].join("\n");
var outline_f32_18_33060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13164018\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233956\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233974\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233959\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233960\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13913733\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233961\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233939\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233924\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233941\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233940\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233971\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233972\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233944\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233928\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300216\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233932\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233953\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233934\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233946\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233963\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F518319\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324086\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233937\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233947\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233927\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233943\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10032\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10032|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/3/6196?source=related_link\">",
"      Verteporfin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33061="Clinical use of saw palmetto";
var content_f32_18_33061=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical use of saw palmetto",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33061/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33061/contributors\">",
"     Robert B Saper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33061/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33061/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33061/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33061/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/18/33061/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracts of the fruit from saw palmetto (Serenoa repens), the American dwarf palm tree (",
"    <a class=\"graphic graphic_picture graphicRef57176 \" href=\"UTD.htm?31/55/32631\">",
"     picture 1",
"    </a>",
"    ), are commonly used to treat benign prostatic hypertrophy (BPH). The first evidence of saw palmetto use for urinary symptoms in men is from Egypt in the 15th century BC [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/1\">",
"     1",
"    </a>",
"    ]. Native Americans in Florida in the early 1700s utilized saw palmetto to treat prostate gland swelling and inflammation, testicular atrophy, and erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 1870s, eclectic medical practitioners used the plant for urologic conditions. Saw palmetto berries were officially listed in the United States Pharmacopoeia in the first half of the 20th century [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/4\">",
"     4",
"    </a>",
"    ]. Although popular in the United States, it is more commonly used in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, phytotherapeutic agents including saw palmetto represent nearly one-half of the treatment of BPH in Italy compared to 5 percent use of both alpha blockers and 5-alpha-reductase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies and meta-analyses have evaluated extracts of the saw palmetto berry for its safety and efficacy in the treatment of BPH; these are reviewed here. Detailed discussions of the treatment of BPH and the use of saw palmetto in the combination herbal product PC-SPES for the treatment of prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=see_link\">",
"     \"Medical treatment of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38520?source=see_link\">",
"     \"Secondary endocrine therapies for castration resistant prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The saw palmetto berry contains over 100 known compounds. The active ingredients in saw palmetto appear to be contained in the purified lipid soluble extract of the saw palmetto berry. This has been found to contain 85 to 95 percent fatty acids (predominantly lauric, caprylic, and caproic), long chain alcohols, and sterols (including beta-sitosterol, stigmasterol, cycloartenol, lupeol, lupenone, and methylcycloartenol) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact mechanisms of action of saw palmetto are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/7\">",
"     7",
"    </a>",
"    ]. Proposed mechanisms include antiandrogenic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]; inhibition of type 1 and type 2 isoenzymes of 5-alpha-reductase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]; inhibition of growth factors such as the insulin-like growth factor-I [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/12\">",
"     12",
"    </a>",
"    ]; relaxation of lower urinary tract smooth muscle through antagonism of muscarinic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/13\">",
"     13",
"    </a>",
"    ]; antiinflammatory effects through inhibition of lipoxygenase, cyclooxygenase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/14\">",
"     14",
"    </a>",
"    ], and leukotrienes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/15\">",
"     15",
"    </a>",
"    ]; alteration of cholesterol metabolism; antiestrogenic effects; and a decrease in available sex hormone-binding globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/7,16-19\">",
"     7,16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a double-blind study examining prostate tissue from 35 men treated with either saw palmetto or placebo for three months prior to prostatectomy for BPH, a significant decrease in nuclear receptors for estrogen, progesterone, and androgen was seen in those men treated with saw palmetto [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/7\">",
"     7",
"    </a>",
"    ]. In another randomized, placebo-controlled trial of 40 men with BPH awaiting surgery, six months of saw palmetto treatment compared to placebo was associated with significant changes in the amount and organization of nuclear chromatin found at biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS/INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Benign prostatic hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Saw palmetto is widely used for treatment of BPH, but there are few data to support its efficacy.",
"   </p>",
"   <p>",
"    A 2012 review of a 2010 meta-analysis of 32 randomized trials (N = 5666) in patients with BPH comparing saw palmetto and placebo did not find any differences in urinary symptom scores, measures of urinary flow, or prostate size: two high-quality long-term trials (N = 582) found no effect of saw palmetto on American Urological Association Symptom Index (AUASI) score (mean difference in score +0.25, 95% CI -0.58 to +1.07); one high-quality one-year trial (N = 225) found no effect on prostate size (mean difference -1.22 mL, CI -3.91 to +1.47 mL); and three high-quality trials lasting 26 to 72 weeks (N = 667) found no effect on urine flow (+0.40",
"    <span class=\"nowrap\">",
"     mL/sec,",
"    </span>",
"    CI -0.30 to +1.09",
"    <span class=\"nowrap\">",
"     mL/sec)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a randomized trial included in the meta-analysis evaluated titration with a well-characterized form of saw palmetto (Serenoa repens) versus placebo in 369 patients with BPH [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/23\">",
"     23",
"    </a>",
"    ]. Saw palmetto dose was increased from 320",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to 640",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at 24 weeks and to 960",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at 48 weeks. Saw palmetto was no more effective than placebo for improving AUASI score or any secondary outcome (nocturia, peak urine flow, postvoid residual volume) at 72 week follow-up.",
"   </p>",
"   <p>",
"    In summary, the largest, most rigorous studies to date with well-characterized preparations of saw palmetto have produced negative results. We recommend not using saw palmetto for the treatment of BPH symptoms in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prostatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data supporting saw palmetto use in the treatment of chronic prostatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/24\">",
"     24",
"    </a>",
"    ]. A one-year randomized controlled trial comparing saw palmetto with finasteride for chronic",
"    <span class=\"nowrap\">",
"     prostatitis/chronic",
"    </span>",
"    pelvic pain syndrome showed no improvement of the NIH Chronic Prostatitis Symptom Index score for the saw palmetto arm [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=see_link\">",
"     \"Chronic prostatitis/chronic pelvic pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a random mail survey of men diagnosed with prostate cancer in Ontario, Canada, 11.8 percent reported use of saw palmetto [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/26\">",
"     26",
"    </a>",
"    ]. Although over half of those using saw palmetto reported using it to treat or cure their prostate cancer, there is no substantive evidence that saw palmetto influences the course of prostate cancer or changes PSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only mild side effects, including headache, nausea, and dizziness, have been noted with the use of saw palmetto&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/1\">",
"     1",
"    </a>",
"    ]. Adverse effects generally have been reported to be comparable to placebo. One study reported hypertension in 3.1 percent of patients receiving saw palmetto [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/27\">",
"     27",
"    </a>",
"    ]. There were no changes in laboratory values. Several studies have demonstrated that saw palmetto does not significantly affect the PSA concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2012 review of a 2010 meta-analysis that examined adverse events in four trials (N = 425), there was no difference in the frequency of adverse events between saw palmetto and placebo (RR 0.94, 95% CI 0.27-3.19) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case report of cholestatic hepatitis was reported with a combination product containing multiple ingredients including saw palmetto [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/31\">",
"     31",
"    </a>",
"    ]. Two cases of acute pancreatitis have also been linked to use of saw palmetto [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. One episode of intraoperative bleeding associated with an elevated bleeding time presumably related to saw palmetto has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/34\">",
"     34",
"    </a>",
"    ]. The authors speculate that this may have resulted from platelet dysfunction caused by cyclooxygenase inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the lack of safety data and its documented hormonal activity, use of saw palmetto is contraindicated in pregnancy and lactation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/35\">",
"     35",
"    </a>",
"    ]. Saw palmetto should be discontinued two weeks prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HERB-DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hormonal activity of saw palmetto could theoretically interfere with oral contraceptives and hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/35\">",
"     35",
"    </a>",
"    ]. Saw palmetto does not appear to interact significantly with the different cytochrome P450 isoforms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. There is a theoretical risk of increased bleeding if combined with antiplatelet drugs or anticoagulants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common dosage of saw palmetto used in clinical trials is 160 mg twice daily of a dried lipophilic extract containing 80 percent to 90 percent fatty acids. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BRAND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different preparations of saw palmetto are available, often including a number of other agents such as Pygeum africanum, zinc, and additional compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/7\">",
"     7",
"    </a>",
"    ]. One study analyzing six different brands of saw palmetto purchased from retail and specialty stores measured the actual saw palmetto content [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/39\">",
"     39",
"    </a>",
"    ]. Measured amounts of saw palmetto extract varied from 3 percent to 140 percent of the stated dosages on the labels. Three products contained less than 20 percent of the stated dosages. One brand showed statistical differences in measured dosage between lots. Similarly, a study of 14 brands of saw palmetto extract found significantly different amounts of free fatty acid content [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/40\">",
"     40",
"    </a>",
"    ]. An in vitro comparison of the inhibition of 5 alpha-reductase by different saw palmetto brands showed wide variation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New Good Manufacturing Practices for the dietary supplement industry have been established by the US FDA and were phased in from 2008 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33061/abstract/42\">",
"     42",
"    </a>",
"    ]. Until it is clear these practices ensure quality, patients who choose to use saw palmetto can use products that have passed specified quality criteria by independent commercial laboratories (",
"    <a class=\"graphic graphic_table graphicRef81955 \" href=\"UTD.htm?43/0/44043\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, large high-quality studies have not shown saw palmetto to be effective for the treatment of BPH. We suggest not treating men with saw palmetto for BPH symptoms (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Benign prostatic hypertrophy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Saw palmetto appears to be well tolerated; serious side effects appear to be rare. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Variability in the quality and purity of available products limits the ability of the clinician to provide sound advice to the patient. If patients do choose to take saw palmetto, a product should be chosen that meets specific quality criteria (",
"      <a class=\"graphic graphic_table graphicRef81955 \" href=\"UTD.htm?43/0/44043\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Brand'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/1\">",
"      Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/2\">",
"      Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 1996; 48:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/3\">",
"      Bennett B, et al. Uses of saw palmetto (Serenoa repens, Arecaceae) in Florida. Econ Bot 1998; 52:381.",
"     </a>",
"    </li>",
"    <li>",
"     DerMarderosian, A. Saw palmetto in the review of natural products. Facts and Comparisons, St. Louis 2000.",
"    </li>",
"    <li>",
"     Blumenthal M, Gruenwald J, Hall T, et al. German Commission E monographs: therapeutic monographs on medicinal plants, American Botanical Council, Austin 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/6\">",
"      Di Silverio F, Flammia GP, Sciarra A, et al. Plant extracts in BPH. Minerva Urol Nefrol 1993; 45:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/7\">",
"      Barrette EP. Use of saw palmetto extract for benign prostatic hyperplasia. Alternative Medicine Alert 1998; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/8\">",
"      Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate 1998; 37:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/9\">",
"      Marks LS, Hess DL, Dorey FJ, et al. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology 2001; 57:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/10\">",
"      Goepel M, Hecker U, Krege S, et al. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. Prostate 1999; 38:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/11\">",
"      Strauch G, Perles P, Vergult G, et al. Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 1994; 26:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/12\">",
"      Wadsworth TL, Carroll JM, Mallinson RA, et al. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 2004; 145:3205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/13\">",
"      Suzuki M, Oki T, Sugiyama T, et al. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 2007; 69:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/14\">",
"      Levin RM, Das AK. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol Res 2000; 28:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/15\">",
"      Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997; 57:299.",
"     </a>",
"    </li>",
"    <li>",
"     Dreikorn K, Richter R. Conservative nonhormonal treatment of patients with benign prostatic hyperplasia. In: New Developments in Biosciences 5, Prostatic Hyperplasia, Ackerman R, Schroeder FH (Eds), Walter de Gruyter and Co, Berlin 1989. p.109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/17\">",
"      Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 1995; 273:607.",
"     </a>",
"    </li>",
"    <li>",
"     McGuire E. Detrusor response to obstruction. Department of Health and Human Services, Bethesda, MD 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/19\">",
"      Di Silverio F, D'Eramo G, Lubrano C, et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 1992; 21:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/20\">",
"      Veltri RW, Marks LS, Miller MC, et al. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. Urology 2002; 60:617.",
"     </a>",
"    </li>",
"    <li>",
"     file://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001423.pub2/abstract (Accessed on June 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/22\">",
"      Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009; :CD001423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/23\">",
"      Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011; 306:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/24\">",
"      Shoskes DA. Phytotherapy in chronic prostatitis. Urology 2002; 60:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/25\">",
"      Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol 2004; 171:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/26\">",
"      Boon H, Westlake K, Stewart M, et al. Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology 2003; 62:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/27\">",
"      Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996; 29:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/28\">",
"      Gerber GS, Zagaja GP, Bales GT, et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998; 51:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/29\">",
"      Braeckman J, et al. Efficacy and safety of the extract of Serenoa repens in the treatment of BPH: therapeutic equivalence between twice and once daily dosage forms. Phytotherapy Res 1997; 11:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/30\">",
"      Braeckman J. The extract of Serenoa repens in the treatment of BPH: A multicenter open study. Curr Ther Res 1994; 55:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/31\">",
"      Hamid S, Rojter S, Vierling J. Protracted cholestatic hepatitis after the use of prostata. Ann Intern Med 1997; 127:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/32\">",
"      Wargo KA, Allman E, Ibrahim F. A possible case of saw palmetto-induced pancreatitis. South Med J 2010; 103:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/33\">",
"      Jibrin I, Erinle A, Saidi A, Aliyu ZY. Saw palmetto-induced pancreatitis. South Med J 2006; 99:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/34\">",
"      Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. J Intern Med 2001; 250:167.",
"     </a>",
"    </li>",
"    <li>",
"     Newall CA, Anderson LA, Phillipson JD. Herbal medicines: A guide for health-care professionals, The Pharmaceutical Press, London 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/36\">",
"      Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/37\">",
"      Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/38\">",
"      Markowitz JS, Donovan JL, Devane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003; 74:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/39\">",
"      Feifer AH, Fleshner NE, Klotz L. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol 2002; 168:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/40\">",
"      Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33061/abstract/41\">",
"      Scaglione F, Lucini V, Pannacci M, et al. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology 2008; 82:270.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/bbs/topcs/NEWS/2007/NEW01657.html (Accessed on October 09, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1388 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33061=[""].join("\n");
var outline_f32_18_33061=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL TRIALS/INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Benign prostatic hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prostatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HERB-DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BRAND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/1388\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1388|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/55/32631\" title=\"picture 1\">",
"      Saw palmetto",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1388|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/0/44043\" title=\"table 1\">",
"      Saw palmetto quality criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17720?source=related_link\">",
"      Chronic prostatitis/chronic pelvic pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8698?source=related_link\">",
"      Medical treatment of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38520?source=related_link\">",
"      Secondary endocrine therapies for castration resistant prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33062="Pneumonia caused by Chlamydophila (Chlamydia) species in children";
var content_f32_18_33062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Dori F Zaleznik, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Jesus G Vallejo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33062/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/18/33062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <em>",
"     Chlamydia",
"    </em>",
"    and",
"    <em>",
"     Chlamydophila",
"    </em>",
"    species are obligate, intracellular bacteria.",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    is a major cause of genital tract and ocular infections worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=see_link\">",
"     \"Genital Chlamydia trachomatis infections in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link\">",
"     \"Chlamydia trachomatis infections in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <em>",
"     Chlamydophila",
"    </em>",
"    (formerly",
"    <em>",
"     Chlamydia",
"    </em>",
"    )",
"    <em>",
"     pneumoniae",
"    </em>",
"    and less often",
"    <em>",
"     Chlamydophila",
"    </em>",
"    (formerly",
"    <em>",
"     Chlamydia",
"    </em>",
"    )",
"    <em>",
"     psittaci",
"    </em>",
"    cause atypical pneumonia.",
"    <em>",
"     C. trachomatis",
"    </em>",
"    typically causes conjunctivitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pneumonia in neonates, but also may affect young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=see_link\">",
"     \"Psittacosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link\">",
"     \"Chlamydia trachomatis infections in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Chlamydophila",
"    </em>",
"    species are unusual bacteria in several ways. The genome of the organisms is only 660 million daltons, smaller than any other prokaryote except mycoplasma. They do not contain a peptidoglycan in the cell wall. The growth cycle of the organism is complex and biphasic, consisting of two distinct entities: elementary (EB) and reticulate bodies (RB) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The form in which the bacterium multiplies is the RB, which is intracellular. Replication occurs within a membrane-bound inclusion. RB are unstable and revert to EB within the inclusion, which then ruptures, causing release of EB, which are the form that survives in the extracellular environment; EB are the infectious particles.",
"   </p>",
"   <p>",
"    The signal that triggers RB to EB reversion is not known. EB attach to epithelial cells and enter cells via a phagosome. Once inside, EB reorganize to RB, which then replicate.",
"   </p>",
"   <p>",
"    Two known species of",
"    <em>",
"     Chlamydophila",
"    </em>",
"    are associated with human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      , which has only the single strain, TWAR, and causes respiratory infection. The genome sequences of strains from Japan and the United States have 90 percent homology, including for outer membrane proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <em>",
"       C. psittaci",
"      </em>",
"      , for which man is an incidental host",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunity to infection with",
"    <em>",
"     Chlamydia",
"    </em>",
"    and",
"    <em>",
"     Chlamydophila",
"    </em>",
"    organisms is short-lived. As a result, reinfection or persistent infection and its associated inflammatory response are common, particularly with ocular and genital infections, in which an ongoing immune reaction can lead to scarring and blindness or infertility, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between",
"    <em>",
"     Chlamydophila",
"    </em>",
"    pulmonary infections and acute airway hyperreactivity has been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In some cases of new wheezing, for example, serologic evidence for",
"    <em>",
"     Chlamydophila",
"    </em>",
"    infection (which may be acute or chronic) has been found. However, the absence of clear documentation of acute infection (by culture or polymerase chain reaction [PCR]) makes it difficult to determine a true etiologic role for",
"    <em>",
"     Chlamydophila",
"    </em>",
"    species in asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHLAMYDOPHILA PNEUMONIAE INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    is the most common",
"    <em>",
"     Chlamydophila",
"    </em>",
"    species to cause human infection. The incidence of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    pneumonia is greatest in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/8\">",
"     8",
"    </a>",
"    ]. Transmission of the organism is thought to be person-to-person.",
"   </p>",
"   <p>",
"    The estimated incidence of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    lower respiratory tract infection among children and adults is 100 cases per 100,000 population; the incidence is greatest in those aged 65 to 79 years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/9\">",
"     9",
"    </a>",
"    ]. Studies from around the world have found evidence of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    pneumonia in 0.3 to 44 percent of children with lower respiratory tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. One study used polymerase chain reaction (PCR) in addition to culture and serology to establish the etiologic agent in 168 ambulatory children with community-acquired pneumonia; the following distribution was noted for the 43 percent of patients in whom a pathogen was found [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      &ndash; 27 percent",
"     </li>",
"     <li>",
"      Viral pathogens &ndash; 20 percent",
"     </li>",
"     <li>",
"      <em>",
"       Mycoplasma pneumoniae",
"      </em>",
"      as the sole agent &ndash; 7 percent",
"     </li>",
"     <li>",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      &ndash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fifteen patients had more than one pathogen identified; six of these had coinfection with",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , and one had coinfection with",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    . In similar studies of children hospitalized with community-acquired pneumonia,",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    was identified in approximately 7 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The true incidence of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    infection is not known because of difficulties in confirming the diagnosis. Epidemiologic studies of",
"    <em>",
"     Chlamydophila",
"    </em>",
"    infection must be interpreted with caution because most of them rely upon serology. Serologic testing is not standardized, and variability in both assay conditions and interpretation of thresholds for positivity complicate comparison of one study to another [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a study that compared culture and serologic diagnosis in 91 patients with lower respiratory infection (74 children, 17 adult), 19 percent had evidence of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/15\">",
"     15",
"    </a>",
"    ]. However, some patients were culture positive without serologic evidence of acute infection, and others were culture negative with antibody titers indicative of acute infection. In addition, several patients were culture positive repeatedly for 12 months. These findings suggest that",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    infection is common, especially in outpatients, but serologic methods of establishing incidence are problematic because of repeated and persistent infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;No distinguishing clinical characteristics identify cases of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    infection. In one study comparing",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    infection to all other causes of pneumonia, no significant differences in symptoms, physical examination findings, or routine laboratory results were apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/15\">",
"     15",
"    </a>",
"    ]. Common features include gradual onset of symptoms, associated pharyngitis, and often hoarseness. Sinusitis frequently accompanies or develops as a complication of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/16\">",
"     16",
"    </a>",
"    ]. Infection with",
"    <em>",
"     Mycoplasma",
"    </em>",
"    spp and respiratory viruses can present in a similar fashion.",
"   </p>",
"   <p>",
"    Asymptomatic or mildly symptomatic infection frequently is seen; however, life-threatening infection can occur. As with other atypical pneumonias, infection with",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    usually presents with a normal white blood cell count, and the chest radiograph typically shows one patchy area of subsegmental infiltration.",
"   </p>",
"   <p>",
"    Extrapulmonary manifestations of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    infections may include [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Meningoencephalitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21769?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"       \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reactive arthritis",
"     </li>",
"     <li>",
"      Myocarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One of the more intriguing associations is a possible link between",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    and coronary artery disease in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25160?source=see_link\">",
"     \"Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither clinical presentation nor radiographic findings distinguish",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    pneumonia from",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    pneumonia, although lobar pneumonia is seen more often with",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=see_link&amp;anchor=H6#H6\">",
"     \"Pneumococcal pneumonia in children\", section on 'Radiographic features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical laboratory methods for identification of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    are suboptimal, due to problems related to availability, technical expertise, reproducibility, and result turnaround times. Thus, it is rare to definitively establish a diagnosis of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    in the clinical setting, and treatment is most often on an empirical basis.",
"   </p>",
"   <p>",
"    Most laboratories are not well equipped to culture",
"    <em>",
"     Chlamydophila",
"    </em>",
"    spp, which requires cell culture techniques. Sputum should not be used for tissue culture; thus, nasopharyngeal swabs must be obtained.",
"   </p>",
"   <p>",
"    Other diagnostic modalities for",
"    <em>",
"     Chlamydophila",
"    </em>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antibody tests (complement fixation and microimmunofluorescence)",
"     </li>",
"     <li>",
"      Antigen detection (direct immunofluorescence [DFA] and enzyme immunoassay [EIA])",
"     </li>",
"     <li>",
"      Polymerase chain reaction (PCR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complement fixation has been the traditional method for diagnosing psittacosis, but the test lacks accuracy because it is based upon detecting lipopolysaccharide antigen, which is shared among all of the",
"    <em>",
"     Chlamydophila",
"    </em>",
"    and",
"    <em>",
"     Chlamydia",
"    </em>",
"    species [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/17\">",
"     17",
"    </a>",
"    ]. Microimmunofluorescence, in contrast, is quite sensitive and specific and can distinguish among species but is not readily available.",
"   </p>",
"   <p>",
"    Direct antigen testing and PCR appear to be the most promising advances. In one study, for example, PCR combined with EIA was compared to DFA or culture [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/19\">",
"     19",
"    </a>",
"    ]. Thirty of 56 patients with respiratory symptoms were found positive by one or more methods. Comparing PCR-EIA with DFA or culture, the sensitivity was 76 percent and specificity 99 percent. PCR-EIA is easier to perform than culture and may nearly match its sensitivity. However, PCR methods are not widely available for clinical diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic testing for",
"    <em>",
"     Chlamydophila",
"    </em>",
"    is not standardized [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/14\">",
"     14",
"    </a>",
"    ]. Multiple studies have shown poor correlation between serology and culture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/14,15,21\">",
"     14,15,21",
"    </a>",
"    ]. Testing for IgG at a single time point is particularly insensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/22\">",
"     22",
"    </a>",
"    ]. A fourfold increase in IgG titer between acute and convalescent serum is more sensitive; however, six to eight weeks may be required for IgG antibodies to appear in primary infections, and convalescent samples obtained earlier may not show an antibody response.",
"   </p>",
"   <p>",
"    Until reliable rapid test methodologies are available, uncertainty will remain in diagnosing acute",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    pneumonia or other respiratory illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there is no rapid way to make the diagnosis of",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    pneumonia, treatment begins with empiric therapy for atypical pneumonia (ie, a macrolide antibiotic with or without additional coverage for",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    depending upon the age of the child and the clinical presentation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27369?source=see_link&amp;anchor=H3#H3\">",
"     \"Outpatient treatment of community-acquired pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    pneumonia in children depends upon age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children &ge;8 years of age and adults &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"       doxycycline",
"      </a>",
"      (2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into two doses [maximum daily dose 200 mg]) for 10 to 14 days",
"     </li>",
"     <li>",
"      Children &lt;8 years &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      (30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into four doses) for 10 to 14 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In randomized and observational studies, newer macrolides, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to a maximum of 500 mg on day one followed by 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day up to a maximum of 250 mg for the next four days) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into two or three doses), have in vitro activity against",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    and appear to have clinical efficacy similar to that of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/11,23-25\">",
"     11,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the treatment course is shorter and adverse effects fewer with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"     azithromycin",
"    </a>",
"    , azithromycin may replace",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    for the treatment of these patients upon further testing.",
"   </p>",
"   <p>",
"    Fluoroquinolones also have activity against",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    , although tetracyclines and macrolides are superior. In addition, fluoroquinolones have not been approved for use in patients younger than 18 years with respiratory tract infections (except for the management of postexposure inhalation anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33062/abstract/26\">",
"     26",
"    </a>",
"    ]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CHLAMYDOPHILA PSITTACI INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psittacine birds are the primary reservoir for psittacosis. The birds may be ill or simply asymptomatic excretors of the organism. Man is an incidental host, with acquisition most commonly occurring by the aerosol route.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of",
"    <em>",
"     C. psittaci",
"    </em>",
"    infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=see_link\">",
"     \"Psittacosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=see_link\">",
"       \"Patient information: Pneumonia in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical features of",
"      <em>",
"       Chlamydophila pneumoniae",
"      </em>",
"      infection include gradual onset of symptoms, associated pharyngitis, hoarseness, and possibly sinusitis. However, none of these is specific for",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      infection. The chest radiograph typically demonstrates a patchy area of subsegmental infiltration. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Confirmation of the diagnosis of",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      requires culture of nasopharyngeal swabs, antibody tests, antigen detection tests, or polymerase chain reaction, although these tests may not be readily available. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      pneumonia begins with empiric treatment for atypical pneumonia (ie, a macrolide antibiotic with or without additional coverage for",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      , depending upon the age of the child and the clinical presentation). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis of",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      is confirmed, the treatment of choice depends upon age (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Specific therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children &ge;8 years of age and adults &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"       doxycycline",
"      </a>",
"      (2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into two doses [maximum daily dose 200 mg]) for 10 to 14 days",
"     </li>",
"     <li>",
"      Children &lt;8 years &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      (30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into four doses) for 10 to 14 days.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      (a five-day course) or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (a 10- to 14-day course) are alternatives to erythromycin.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/1\">",
"      Rours GI, Hammerschlag MR, Van Doornum GJ, et al. Chlamydia trachomatis respiratory infection in Dutch infants. Arch Dis Child 2009; 94:705.",
"     </a>",
"    </li>",
"    <li>",
"     Jones RB. Introduction to Chlamydial diseases. In: Principles and Practice of Infectious Diseases, 4th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, New York 1995. p.1676.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/3\">",
"      Shirai M, Hirakawa H, Kimoto M, et al. Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA. Nucleic Acids Res 2000; 28:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/4\">",
"      Shirai M, Hirakawa H, Ouchi K, et al. Comparison of outer membrane protein genes omp and pmp in the whole genome sequences of Chlamydia pneumoniae isolates from Japan and the United States. J Infect Dis 2000; 181 Suppl 3:S524.",
"     </a>",
"    </li>",
"    <li>",
"     Morrison RP, Manning DS, Caldwell HD. Immunology of Chlamydia trachomatis infections. In: Immunology of Chlamydia trachomatis infections, Quinn TC (Ed), Raven Press, New York 1992. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/6\">",
"      Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 1994; 148:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/7\">",
"      Emre U, Sokolovskaya N, Roblin PM, et al. Detection of anti-Chlamydia pneumoniae IgE in children with reactive airway disease. J Infect Dis 1995; 172:265.",
"     </a>",
"    </li>",
"    <li>",
"     Myhra W, Mordhorst CH, Wang SP, et al. Clinical features of Chlamydia pneumoniae, strain TWAR, infection in Denmark 1975-1987. In: Chlamydial Infections, Bowie WR, Caldwell HD, Jones RP (Eds), Cambridge University Press, New York 1980. Vol 1990, p.422.",
"    </li>",
"    <li>",
"     Jackson LA. Chlamydia (Chlamydophila) pneumoniae. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2258.",
"    </li>",
"    <li>",
"     Hammerschlag MR. Chlamydia pneumonia. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2655.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/11\">",
"      Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999; 18:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/12\">",
"      Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/13\">",
"      Kurz H, G&ouml;pfrich H, Wabnegger L, Apfalter P. Role of Chlamydophila pneumoniae in children hospitalized for community-acquired pneumonia in Vienna, Austria. Pediatr Pulmonol 2009; 44:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/14\">",
"      Tuuminen T, Palom&auml;ki P, Paavonen J. The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Methods 2000; 42:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/15\">",
"      Chirgwin K, Roblin PM, Gelling M, et al. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis 1991; 163:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/16\">",
"      Grayston JT, Aldous MB, Easton A, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 1993; 168:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/17\">",
"      Bourke SJ, Lightfoot NF. Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis. Thorax 1995; 50 Suppl 1:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/18\">",
"      Suesaowalak M, Cheung MM, Tucker D, et al. Chlamydophila pneumoniae myopericarditis in a child. Pediatr Cardiol 2009; 30:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/19\">",
"      Kauppinen MT, L&auml;hde S, Syrj&auml;l&auml; H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Arch Intern Med 1996; 156:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/20\">",
"      Murdoch DR. Molecular genetic methods in the diagnosis of lower respiratory tract infections. APMIS 2004; 112:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/21\">",
"      Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/22\">",
"      Gaydos CA, Roblin PM, Hammerschlag MR, et al. Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 1994; 32:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/23\">",
"      Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/24\">",
"      Numazaki K, Sakamoto Y, Umetsu M, et al. Therapeutic effect of clarithromycin for respiratory-tract infections in children caused by Chlamydia pneumoniae. Research Group of Sapporo for Pediatric Chlamydial Infections. Int J Antimicrob Agents 2000; 13:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/25\">",
"      Lee PI, Wu MH, Huang LM, et al. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. J Microbiol Immunol Infect 2008; 41:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33062/abstract/26\">",
"      Meyerhoff A, Albrecht R, Meyer JM, et al. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin Infect Dis 2004; 39:303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5957 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33062=[""].join("\n");
var outline_f32_18_33062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHLAMYDOPHILA PNEUMONIAE INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CHLAMYDOPHILA PSITTACI INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21769?source=related_link\">",
"      Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25160?source=related_link\">",
"      Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=related_link\">",
"      Epidemiology, pathogenesis, and etiology of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27369?source=related_link\">",
"      Outpatient treatment of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=related_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=related_link\">",
"      Pneumococcal pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/14/8425?source=related_link\">",
"      Psittacosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33063="Clinical manifestations and diagnosis of cutaneous leishmaniasis";
var content_f32_18_33063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of cutaneous leishmaniasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/contributors\">",
"     Naomi Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H83446430\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leishmaniasis consists of a complex of vector-borne diseases caused by a heterogeneous group of protozoa belonging to the genus Leishmania; it is transmitted by sand fly vectors. Clinical manifestations range from cutaneous ulcers to systemic multiorgan disease. Specific organisms are frequently associated with a typical clinical picture (",
"    <a class=\"calc graphicRef86988 \" href=\"UTD.htm?0/3/51\">",
"     table 1",
"    </a>",
"    ), although this can be variable.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of cutaneous leishmaniasis (CL) will be reviewed here. Issues concerning treatment, epidemiology, and control are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-of-cutaneous-leishmaniasis?source=see_link\">",
"     \"Treatment of cutaneous leishmaniasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/15/23797?source=see_link\">",
"     \"Epidemiology and control of cutaneous leishmaniasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446472\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period for symptomatic cutaneous leishmaniasis (CL) ranges from weeks to months; mucosal involvement may occur years following initial infection [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Asymptomatic infection may occur in about 10 percent of patients; this has been suggested by delayed hypersensitivity skin testing [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leishmania causes a spectrum of cutaneous disease. The range of clinical manifestations may be attributed to variability in parasite virulence (and other intrinsic characteristics) and variability in the host immune response. At one end of the spectrum, mucosal leishmaniasis (ML) and leishmaniasis recidivans (LR) are caused by oligoparasitic disease associated with a marked cellular immune response. The center of the spectrum consists of localized cutaneous leishmaniasis (LCL), which is the most common clinical presentation. At the opposite end of the spectrum, diffuse cutaneous leishmaniasis (DCL) is caused by polyparasitic disease with a predominance of parasitized macrophages and no granulomatous inflammation. This spectrum of clinical presentation and host immune response is similar to clinical manifestations observed in the setting of leprosy [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cutaneous syndromes associated with Leishmania parasite infection include LCL, LR, DCL, and ML. These will be further described below; they are presented in order of relative clinical frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446480\">",
"    <span class=\"h2\">",
"     Localized cutaneous leishmaniasis (LCL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous lesions tend to occur on exposed areas of the skin; sand fly mouthparts generally cannot penetrate through clothing. Sand fly bite reactions are generally pruritic, but usually do not enlarge; they may resolve slowly over weeks (even in the absence of parasitic infection).",
"   </p>",
"   <p>",
"    LCL begins as a pink-colored papule that enlarges and develops into a nodule or plaque-like lesion (often with central softening), leading to a painless ulceration with an indurated border (",
"    <a class=\"graphic graphic_picture graphicRef64620 \" href=\"UTD.htm?24/2/24608\">",
"     picture 1",
"    </a>",
"    ). In Old World CL, the ulcer is often covered with a hyperkeratotic eschar (",
"    <a class=\"graphic graphic_picture graphicRef87207 \" href=\"UTD.htm?25/49/26390\">",
"     picture 2",
"    </a>",
"    ). In New World CL, the ulcer may be covered with thick white-yellow fibrinous material (",
"    <a class=\"graphic graphic_picture graphicRef86992 \" href=\"UTD.htm?43/38/44647\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Multiple lesions may be present. The clinical appearance can be variable and may include sporotrichoid, verrucous, zosteriform, psoriaform, eczematous,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erysipeloid features [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/5\">",
"     5",
"    </a>",
"    ]. Small satellite lesions may develop just outside the",
"    <span class=\"nowrap\">",
"     plaque/ulcer.",
"    </span>",
"    Spread of lesions along the draining lymphatics may be observed; these may or may not ulcerate, but can be palpated subcutaneously and proximally along the lymphatic chain leading from the primary lesion (nodular lymphangitis). Regional adenopathy can occur and may be prominent in some cases [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary bacterial infection of the ulcer may occur and may be associated with purulent drainage and local cellulitis. Bacterial superinfection may lead to enlargement of the primary lesion and contribute to its persistence.",
"   </p>",
"   <p>",
"    The natural history of LCL consists of gradual healing over months to years; the time varies depending on the species and lesion size [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Leishmaniasis heals with an atrophic, depressed scar; it can also heal as a keloid (in patients predisposed to keloid scarring). Following resolution of the initial lesion(s), it is possible that reactivation of the initial lesion(s) may develop during the subsequent year (or later for ML).",
"   </p>",
"   <p>",
"    There are some distinguishing clinical features between species, although significant overlap may occur; speciation should not be based solely on clinical manifestations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      L.L. major infection (Old World CL) typically has a short incubation period, and ulcers may expand in one to two months to &ge;6 cm in diameter. Multiple lesions are common. Frequently, ulcers are covered with a thick crust, and nodular, plaque-like lesions are common. Epithelialization of the ulcer bed usually occurs within six months.",
"     </li>",
"     <li>",
"      L.L. tropica infection (Old World CL) is typically a more chronic infection than CL due to L.L. major; it evolves over months to years. The skin lesions are relatively few in number and sometimes relatively small (1 to 2 cm). Facial lesions may be larger, and a predilection for the nose and forehead may be observed. The lesions are very dry and appear crusted. Spontaneous resolution is slow, usually over one to two years or longer. L.L. tropica can be associated with the complication of Leishmania recidivans (LR). (See",
"      <a class=\"local\" href=\"#H83446505\">",
"       'Leishmaniasis recidivans (LR)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      L.L. aethiopica infection (Old World CL) usually consists of a solitary facial lesion with or without surrounding satellite papules, which coalesce into spreading nodules or plaques. Lesions may spread along mucocutaneous margins but do not involve the oral or nasal mucosa. L.L. aethiopica is associated with relatively long chronicity. Histologically, relatively little inflammation is seen.",
"     </li>",
"     <li>",
"      L.L. infantum-chagasi infection can cause a small number of slow-growing nodular lesions that persist for years. This is an Old World species most often associated with visceral leishmaniasis, but it can also cause CL; its presence in the skin does not imply coexistent visceral disease.",
"     </li>",
"     <li>",
"      L.L. mexicana (New World CL) infection generally produces small, chronic skin ulcers, usually one or few in number. Lesions on the ear are called &ldquo;Chiclero&rsquo;s ulcer,&rdquo; which reflects the biting habits of the sand fly vector. L.L. mexicana lesions may spontaneously heal relatively quickly; one study noted 88 percent of lesions healed by 14 weeks [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      L.V. braziliensis (New World CL) infection causes are large lesions, frequently with lymphocutaneous involvement. A sporotrichoid pattern of multiple ulcers or nodular lymphangitis is common (",
"      <a class=\"graphic graphic_picture graphicRef64620 \" href=\"UTD.htm?24/2/24608\">",
"       picture 1",
"      </a>",
"      ). Lymphadenopathy, fever, and malaise may precede development of any lesion [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/8\">",
"       8",
"      </a>",
"      ]. Ulcers may heal in 6 to 12 months, but can be quite persistent. L.V. braziliensis CL may be associated with mucosal leishmaniasis concurrently or subsequently.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1961622\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of LCL includes bacterial infection, cutaneous myiasis, pyoderma gangrenosum, ecthyma, impetigo, cutaneous malignancy, sarcoidosis, prurigo nodularis, lichen simplex chronicus, spider bite, tropical ulcer, yaws, cutaneous anthrax, nocardia and actinomycosis, cutaneous tuberculosis, nontuberculous mycobacteria such as M. marinum, M. fortuitum, less likely Buruli ulcer (M. ulcerans), and fungal infections such as sporotrichosis, blastomycosis, and chromoblastomycosis.",
"   </p>",
"   <p>",
"    Clinical features that may help differentiate CL from these entities include its chronicity, general painlessness, frequent clustering of lesions, occurrence on an exposed location, and orientation of skin lesion along skin creases. Other important distinguishing characteristics include the presence of inflammatory satellite papules, subcutaneous induration beneath lesion, ulcerations with well-defined indurated borders, and presence of subcutaneous nodules [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446505\">",
"    <span class=\"h2\">",
"     Leishmaniasis recidivans (LR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;LR refers to a relatively uncommon syndrome caused by L.L. tropica infection. Following healing of the primary lesion, persistent organisms can cause new papules to form around the margin of the scar. Skin biopsy demonstrates few parasites, but a robust granulomatous, cell-mediated immune response. LR can occur following trauma in the area of a prior lesion many years after initial healing [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446520\">",
"    <span class=\"h2\">",
"     Diffuse cutaneous leishmaniasis (DCL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;DCL is a rare syndrome that occurs mainly in the setting of L.L. aethiopica, L.L. mexicana, and L.L. amazonensis infection. It begins as a localized lesion that does not ulcerate; rather, amastigotes disseminate to macrophages in other areas of the skin. In general, soft nodules or plaques form on the face and extensor limb surfaces, but the entire body may be involved. Histologically, many parasites are seen, but there is scarce lymphocytic reaction. Patients with DCL usually have a defect in the cell-mediated immune response and are anergic to Leishmania antigen. DCL reported in AIDS patients has involved other parasites species such as L.L. major and L.V. guyanensis [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/11\">",
"     11",
"    </a>",
"    ]. Successful treatment of DCL is difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446528\">",
"    <span class=\"h2\">",
"     Mucosal leishmaniasis (ML)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ML, also known as espundia, occurs in the New World and is caused by the Viannia subgenus, especially L.V. braziliensis, L.V. guyanensis, and L.V. panamensis, but also L.L. amazonensis [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/12\">",
"     12",
"    </a>",
"    ]. ML due to Old World species L.L. infantum and L.L. aethiopica has been described among immunocompromised hosts. (See",
"    <a class=\"local\" href=\"#H83446544\">",
"     'CL in immunocompromised hosts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of ML due to L.V. braziliensis infection is higher in South America (particularly Bolivia, Peru, and Brazil) than in Central America. Overall, the risk of mucosal disease following a primary CL lesion is less than 5 percent. ML can occur concurrently or following partially treated or untreated CL. Concurrent ML has been described in up to 28 percent of cases; subsequent ML can occur up to 10 years or more following CL [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ML is characterized by mucosal destruction. Symptoms include nasal stuffiness or blockage, mucosal bleeding, increased secretions, and sloughing of dead tissue. Some have pain, deformity, and inflammation (",
"    <a class=\"graphic graphic_picture graphicRef86914 \" href=\"UTD.htm?36/22/37221\">",
"     picture 4",
"    </a>",
"    ). Erosion of mucosal surfaces occurs, most commonly in the nose, mouth, or nasal septum (eg, in the form of cartilage perforation). Other involved areas may include the cheek, pharynx, palate, epiglottis, larynx, trachea, and genitalia. Hoarseness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a brassy cough are suggestive of laryngeal involvement. The disease is considered mild in the setting of isolated nasal stuffiness, moderate if there is associated odynophagia or dysphonia, and severe if there is respiratory distress or severe dysphonia.",
"   </p>",
"   <p>",
"    Substantial disfigurement can result from destruction of the nasal cartilage and surrounding tissues. Rarely, aspiration, respiratory compromise,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death can occur. Any patient with New World CL and nasal, oral, or hypopharyngeal symptoms should undergo visual inspection of all mucosal surfaces of the hypopharynx, including the vocal cords and oronasal pharynx. Abnormal appearing tissue should be biopsied and polymerase chain reaction (PCR) for Leishmania should be performed.",
"   </p>",
"   <p>",
"    Histopathology generally demonstrates a robust cell mediated immune response, and large quantities of cytokine production, T lymphocyte proliferation, and neutrophils expressing proteinases have been observed [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/14\">",
"     14",
"    </a>",
"    ]. In general, relatively few parasites are observed in mucosal lesions.",
"   </p>",
"   <p>",
"    Leishmania RNA Virus 1 (LRV1), an endosymbiont of L.V. guyanensis and some L.V. braziliensis organisms, may augment infection and may also be associated with metastatic involvement. It acts as an immunogen and elicits a hyperinflammatory immune response through toll like receptor 3 (TLR3) [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446544\">",
"    <span class=\"h2\">",
"     CL in immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of intracellular Leishmania infection requires a Th1 dependent cell-mediated immune response including cells (CD4 and CD8 T cells, natural killer, dendritic cells, macrophages) and cytokines (interferon gamma, TNF alpha, IL-12).",
"   </p>",
"   <p>",
"    Patients with immunosuppressing conditions are at increased risk for more severe CL. This includes patients on chronic corticosteroids, biologic modulators, or other immunosuppressive drugs; organ transplant recipients, pregnant patients, and patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reactivation of CL and dissemination or progression to ML has been noted after chronic corticosteroid use. It has also been observed that application of topical steroids to CL lesions leads to increased numbers of amastigotes on skin biopsy, suggesting that corticosteroids may contribute to local disruption of immune regulation [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biologic immunomodulators (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ) have been associated with both primary and reactivation CL [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CL is relatively unusual among organ transplant recipients; it has been observed in the Mediterranean region with onset long after transplant (median 18 months, range 6 to 19 months) [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/19\">",
"       19",
"      </a>",
"      ]. Other relatively unusual observations include a case of DCL due to L.L. major (a species not usually associated with dissemination outside the skin) and some CL cases with multiple lesions consisting of nodular rather than ulcerative appearance [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV-induced immunosuppression has been associated with CL primary infection as well as reactivation, since Leishmania parasites are capable of persisting in scars of prior lesions [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/21\">",
"       21",
"      </a>",
"      ]. CL in patients with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      has also been associated with disseminated disease, especially in the setting of CD4",
"      <span class=\"nowrap\">",
"       &lt;200/mm&sup3;.",
"      </span>",
"      Manifestations include disseminated CL due to L.L. major, rapid progression of New World CL to ML, and ML due to L.L. infantum-chagasi. Patients with",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      may be less responsive to treatment than other patients and may require suppressive therapy until immune reconstitution occurs. Such patients are also at risk for immune reconstitution inflammatory syndrome (IRIS) [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy &gt;18 weeks has been associated with large (up to 6 cm",
"      <sup>",
"       2",
"      </sup>",
"      ), exophytic, &ldquo;cauliflower like&rdquo; CL lesions [",
"      <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446552\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1961629\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cutaneous leishmaniasis",
"    <strong>",
"    </strong>",
"    (CL) should be considered in patients with one or more chronic skin lesions and a history of exposure in an area where leishmaniasis is endemic. Definitive diagnosis requires demonstration of the parasite in a clinical specimen (usually skin) by histology, culture, or molecular analysis via polymerase chain reaction (PCR). To maximize diagnostic yield, ideally all three diagnostic tests are warranted on the initial sample if feasible. If not, all tests can be performed, then histology and PCR may provide sufficient information. Parasitologic diagnosis to the level of the Leishmania species should be pursued, since this information may influence determination of treatment.",
"   </p>",
"   <p>",
"    Reference laboratory support is available; laboratories should be contacted before diagnostic samples are obtained to obtain instructions and transport media. In the United States, the",
"    <a class=\"external\" href=\"file://www.dpd.cdc.gov/dpdx/HTML/DiagnosticProcedures.htm\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    (CDC) offers diagnostic services. The CDC Parasitic Disease Public Inquiries may be contacted at 404-718-4745 (email parasites@cdc.gov). The Walter Reed Army Institute of Research",
"    <a class=\"external\" href=\"file://wrair-www.army.mil/OtherServices_LDL.aspx\">",
"     Leishmania Diagnostics Laboratory",
"    </a>",
"    (email leishmania@amedd.army.mil) also provides diagnostic services. In Canada, the",
"    <a class=\"external\" href=\"file://www.nrcp.ca/\">",
"     National Reference Centre for Parasitology",
"    </a>",
"    offers diagnostic support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446560\">",
"    <span class=\"h2\">",
"     Specimen collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimens should be collected from lesions that appear active and ulcerative, without evidence of secondary infection. The lesion should be cleaned gently with soap and water or povidone-iodine and then washed with saline; residual iodine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ethanol should be avoided if culture is planned.",
"    <strong>",
"    </strong>",
"    The base and margins of ulcerative lesions should be scraped gently with a sterile scalpel blade or lancet.",
"    <strong>",
"    </strong>",
"    The tissue collected should be submitted for histology, culture, and PCR.",
"   </p>",
"   <p>",
"    Nodular lesions, plaque-like lesions, and lesions on the face (or other sensitive areas) may be sampled via injection and withdrawal of nonbacteriostatic normal saline at three to five sites. The aspirate may be submitted for culture and PCR. An alternative technique for sample collection consists of skin snips of the indurated margins of a lesion.",
"   </p>",
"   <p>",
"    A full thickness punch biopsy of the skin (4 to 5 mm) allows evaluation of histology and cellular response; it may also be submitted for culture to evaluate for leishmaniasis, acid-fast mycobacteria, and fungi. The preferred site for skin biopsy is the raised border of an ulcerative lesion (",
"    <a class=\"graphic graphic_picture graphicRef86992 \" href=\"UTD.htm?43/38/44647\">",
"     picture 3",
"    </a>",
"    ). Following biopsy, the sample should be gently blotted and then touched to a clean glass slide for multiple &ldquo;touch prep&rdquo; smears. (See",
"    <a class=\"local\" href=\"#H83446574\">",
"     'Histology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1961071\">",
"    <span class=\"h2\">",
"     Diagnostic tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tools include histology, culture, and molecular diagnostic techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446574\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Leishmania amastigote is an oval to round organism 1.5 to 4.0 microns in diameter with a distinct cell membrane, cytoplasm, internal nucleus, and rod-shaped kinetoplast containing mitochondrial DNA (",
"    <a class=\"graphic graphic_picture graphicRef86989 \" href=\"UTD.htm?18/34/18983\">",
"     picture 5",
"    </a>",
"    ). Giemsa staining is typically used; with this stain, the cytoplasm is blue, the nucleus violet-blue, and the kinetoplast red to violet (a critical diagnostic characteristic). These findings may be observed on histology or touch prep smears.",
"   </p>",
"   <p>",
"    A tissue Gram stain can be useful to highlight the kinetoplast in tissue samples, although hematoxylin and eosin staining is usually sufficient. The parasites are found in macrophages in the upper dermis and are often surrounded by dermal chronic inflammation with lymphocytes, macrophages, plasma cells, and sometimes necrotizing granulomas. Organisms may be scarce in chronic lesions such as leishmaniasis recidivans (LR) and L.V. braziliensis infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446586\">",
"    <span class=\"h3\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;In appropriate culture media, tissue amastigotes may be converted to promastigotes. In one study including 202 skin lesions comparing diagnostic methods for CL in Peru, culture and smear were less useful for skin lesions of a duration &lt;3 months or &gt;12 months or for nonulcerative lesions [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typical liquid media consists of Schneider&rsquo;s drosophila media supplemented with calf serum, or Novy, MacNeal, Nicolle (NNN) media. Leishmania grows best at 26&deg;C; the rate of growth depends on the number of parasites in the tissue, species growth characteristics, and absence of secondary bacterial contamination from the skin (which can overgrow the culture).",
"   </p>",
"   <p>",
"    Expansion of the parasite in culture permits speciation using isoenzyme electrophoretic patterns [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/28\">",
"     28",
"    </a>",
"    ]. Direct staining of cultured parasites or tissues with monoclonal antibodies can also be performed in some laboratories.",
"   </p>",
"   <p>",
"    Culture for acid-fast bacilli and fungi may also be pursued to evaluate potential alternative diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446605\">",
"    <span class=\"h3\">",
"     Molecular diagnostic techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) is one of the most sensitive diagnostic tests for CL. High performance characteristics have been reported compared with histology, culture, and smear [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. In one study including 202 skin lesions comparing diagnostic methods for CL in Peru, PCR had the greatest sensitivity irrespective of lesion characteristics [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and specificity of the SMART Leish PCR (Cepheid) for the genus assay are 99 and 67 percent, respectively. The genus real-time PCR (RT-PCR) can detect at least four genome copies of Leishmania DNA [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/30\">",
"     30",
"    </a>",
"    ]. The sensitivity and specificity of the SMART Leish-L major assay for the species assay are 95 and 91 percent, respectively. RT-PCR has also been used for identification of Leishmania species [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1961389\">",
"    <span class=\"h2\">",
"     Other assays",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446613\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clinical role for serology in the diagnosis of CL; the sensitivity and specificity are variable and antibody levels are generally low. Most serologic assays cannot reliably distinguish between present and past infection. The sensitivity of serology may be higher in the setting of mucosal leishmaniasis (ML), and antibodies may decrease after treatment [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic tests for visceral leishmaniasis can be cross-reactive in the setting of CL; these include the rK39 antibody test, such as the KalazarDetect rapid test and ELISA (Inbios) [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83446621\">",
"    <span class=\"h3\">",
"     Skin test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Montenegro or Leishmaniasis skin test has been evaluated in research studies and is widely used in South America, though no preparation has been approved for human use in the United States. The test consists of intradermal injection of killed promastigotes; it is positive in 82 to 89 percent of cases of localized CL [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/35\">",
"     35",
"    </a>",
"    ]. The test is read 48 or 72 hours after intradermal injection; &ge;5 mm induration is considered positive. The test cannot distinguish between active and resolved infection.",
"   </p>",
"   <p>",
"    An interferon gamma release assay for leishmaniasis has been developed for epidemiologic purposes but is not commercially available [",
"    <a class=\"abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1961886\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leishmania causes a spectrum of cutaneous disease. Mucosal leishmaniasis (ML) and leishmaniasis recidivans (LR) are caused by oligoparasitic disease associated with a marked cellular immune response. Diffuse cutaneous leishmaniasis (DCL) is caused by polyparasitic disease with a predominance of parasitized macrophages and no granulomatous inflammation. The center of the spectrum consists of localized cutaneous leishmaniasis (LCL), which is the most common clinical presentation. (See",
"      <a class=\"local\" href=\"#H83446472\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LCL consists of cutaneous lesions on exposed areas of the skin. It begins as a pink-colored papule that enlarges and develops into a nodule or plaque-like lesion (often with central softening), leading to a painless ulceration with an indurated border (",
"      <a class=\"graphic graphic_picture graphicRef64620 \" href=\"UTD.htm?24/2/24608\">",
"       picture 1",
"      </a>",
"      ). In Old World cutaneous leishmaniasis (CL), the ulcer is often covered with a hyperkeratotic eschar (",
"      <a class=\"graphic graphic_picture graphicRef87207 \" href=\"UTD.htm?25/49/26390\">",
"       picture 2",
"      </a>",
"      ). In New World CL, the ulcer may be covered with thick white-yellow fibrinous material (",
"      <a class=\"graphic graphic_picture graphicRef86992 \" href=\"UTD.htm?43/38/44647\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H83446480\">",
"       'Localized cutaneous leishmaniasis (LCL)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with immunosuppressing conditions are at increased risk for more severe CL. These groups include patients on chronic corticosteroids, biologic modulators or other immunosuppressive drugs, organ transplant recipients, pregnant patients, and patients with",
"      <span class=\"nowrap\">",
"       HIV/AIDS.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H83446544\">",
"       'CL in immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CL should be considered in patients with one or more chronic skin lesions and a history of exposure in an area where leishmaniasis is endemic. Definitive diagnosis requires demonstration of the parasite in a clinical specimen (usually skin) by histology, culture, or molecular analysis via polymerase chain reaction (PCR). Parasitologic diagnosis to the level of the Leishmania species should be pursued if feasible, since this information may influence determination of treatment. (See",
"      <a class=\"local\" href=\"#H83446552\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13572023\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Karin Leder and Dr. Peter Weller, who contributed to an earlier version of this topic review.",
"   </p>",
"   <p>",
"    The content and views expressed in this publication are the sole responsibility of the author and do not necessarily reflect the views or policies of the Department of Defense or the US Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the US Government.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/1\">",
"      Melby PC. Experimental leishmaniasis in humans: review. Rev Infect Dis 1991; 13:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/2\">",
"      Jones TC, Johnson WD Jr, Barretto AC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/3\">",
"      Follador I, Ara&uacute;jo C, Bacellar O, et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 2002; 34:E54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/4\">",
"      Convit J, Ulrich M, Fern&aacute;ndez CT, et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993; 87:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/5\">",
"      Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/6\">",
"      Sousa Ade Q, Parise ME, Pompeu MM, et al. Bubonic leishmaniasis: a common manifestation of Leishmania (Viannia) braziliensis infection in Ceara, Brazil. Am J Trop Med Hyg 1995; 53:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/7\">",
"      Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/8\">",
"      Barral A, Guerreiro J, Bomfim G, et al. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. Am J Trop Med Hyg 1995; 53:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/9\">",
"      Kubba R, Al-Gindan Y, el-Hassan AM, Omer AH. Clinical diagnosis of cutaneous leishmaniasis (oriental sore). J Am Acad Dermatol 1987; 16:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/10\">",
"      Marovich MA, Lira R, Shepard M, et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis 2001; 33:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/11\">",
"      Develoux M, Diallo S, Dieng Y, et al. Diffuse cutaneous leishmaniasis due to Leishmania major in Senegal. Trans R Soc Trop Med Hyg 1996; 90:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/12\">",
"      Guerra JA, Prestes SR, Silveira H, et al. Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis 2011; 5:e980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/13\">",
"      Marsden PD. Mucosal leishmaniasis (\"espundia\" Escomel, 1911). Trans R Soc Trop Med Hyg 1986; 80:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/14\">",
"      Boaventura VS, Santos CS, Cardoso CR, et al. Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17-related cytokines. Eur J Immunol 2010; 40:2830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/15\">",
"      Ives A, Ronet C, Prevel F, et al. Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 2011; 331:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/16\">",
"      Motta AC, Arruda D, Souza CS, Foss NT. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol 2003; 42:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/17\">",
"      Tuon FF, Sabbaga Amato V, Floeter-Winter LM, et al. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report. Int J Dermatol 2007; 46:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/18\">",
"      Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012; 71 Suppl 2:i60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/19\">",
"      Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/20\">",
"      Mirzabeigi M, Farooq U, Baraniak S, et al. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol 2006; 33:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/21\">",
"      Mendon&ccedil;a MG, de Brito ME, Rodrigues EH, et al. Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 2004; 189:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/22\">",
"      Lindoso JA, Barbosa RN, Posada-Vergara MP, et al. Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World. Br J Dermatol 2009; 160:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/23\">",
"      Chrusciak-Talhari A, Ribeiro-Rodrigues R, Talhari C, et al. Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis. Am J Trop Med Hyg 2009; 81:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/24\">",
"      Couppi&eacute; P, Clyti E, Sobesky M, et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004; 151:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/25\">",
"      Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis 2007; 45:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/26\">",
"      Douba MD, Abbas O, Wali A, et al. Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo. J Eur Acad Dermatol Venereol 2012; 26:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/27\">",
"      Boggild AK, Ramos AP, Espinosa D, et al. Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. Am J Trop Med Hyg 2010; 83:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/28\">",
"      Kreutzer RD, Christensen HA. Characterization of Leishmania spp. by isozyme electrophoresis. Am J Trop Med Hyg 1980; 29:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/29\">",
"      Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 2007; 45:21.",
"     </a>",
"    </li>",
"    <li>",
"     The SMART Leish http:/www.accessdata.fda.gov/cdrh_docs/pdf8/K081868.pdf (Accessed on September 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/31\">",
"      Antinori S, Calattini S, Piolini R, et al. Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis? Am J Trop Med Hyg 2009; 81:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/32\">",
"      Marfurt J, Niederwieser I, Makia ND, et al. Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis 2003; 46:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/33\">",
"      Romero GA, de la Gl&oacute;ria Orge Orge M, de Farias Guerra MV, et al. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Trop 2005; 93:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/34\">",
"      Hartzell JD, Aronson NE, Weina PJ, et al. Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis. Am J Trop Med Hyg 2008; 79:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/35\">",
"      Shaw JJ, Lainson R. Leishmaniasis in Brazil: X. Some observations of intradermal reactions to different trypanosomatid antigens of patients suffering from cutaneous and mucocutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1975; 69:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./clinical-manifestations-and-diagnosis-of-cutaneous-leishmaniasis/abstract/36\">",
"      Turgay N, Balcioglu IC, Toz SO, et al. Quantiferon-Leishmania as an epidemiological tool for evaluating the exposure to Leishmania infection. Am J Trop Med Hyg 2010; 83:822.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5689 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33063=[""].join("\n");
var outline_f32_18_33063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1961886\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83446430\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83446472\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83446480\">",
"      Localized cutaneous leishmaniasis (LCL)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1961622\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83446505\">",
"      Leishmaniasis recidivans (LR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83446520\">",
"      Diffuse cutaneous leishmaniasis (DCL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83446528\">",
"      Mucosal leishmaniasis (ML)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83446544\">",
"      CL in immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83446552\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1961629\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83446560\">",
"      Specimen collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1961071\">",
"      Diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83446574\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83446586\">",
"      - Culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83446605\">",
"      - Molecular diagnostic techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1961389\">",
"      Other assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83446613\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83446621\">",
"      - Skin test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1961886\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13572023\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5689\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5689|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/2/24608\" title=\"picture 1\">",
"      New World CL ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/49/26390\" title=\"picture 2\">",
"      Old World CL due to L major",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/38/44647\" title=\"picture 3\">",
"      New World CL ulcer with fibrinous material",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/22/37221\" title=\"picture 4\">",
"      Mucosal leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/34/18983\" title=\"picture 5\">",
"      Leishmania amastigote",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/15/23797?source=related_link\">",
"      Epidemiology and control of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18105?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-of-cutaneous-leishmaniasis?source=related_link\">",
"      Treatment of cutaneous leishmaniasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33064="Glomerular diseases due to nonamyloid fibrillar deposits";
var content_f32_18_33064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glomerular diseases due to nonamyloid fibrillar deposits",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33064/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33064/contributors\">",
"     Fernando C Fervenza, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33064/contributors\">",
"     Sanjeev Sethi, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33064/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33064/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33064/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/18/33064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular disease may be associated with the appearance of fibrillar deposits in the mesangium or glomerular basement membrane. The fibrils are Congo red-positive in",
"    <strong>",
"     amyloidosis",
"    </strong>",
"    and Congo red-negative in other forms. The most common forms of Congo red-negative (non-amyloid) fibrillar glomerular deposition diseases are",
"    <strong>",
"     fibrillary glomerulonephritis",
"    </strong>",
"    and",
"    <strong>",
"     immunotactoid glomerulopathy",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Fibrillary glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/1-6\">",
"     1-6",
"    </a>",
"    ] and immunotactoid glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,5-9\">",
"     3,5-9",
"    </a>",
"    ] are uncommon causes of glomerular disease. Both disorders probably result from deposits derived from immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/9\">",
"     9",
"    </a>",
"    ]. The pathognomonic histologic findings are seen on electron microscopy. By comparison, other forms of nonamyloid fibrillary deposition disease have been described in which the deposits are composed of fibronectin (fibronectin glomerulopathy) or atypical type III collagen fibrils (collagenofibrotic glomerulopathy). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology and pathogenesis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Other fibrillary disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Glomerular disease associated with amyloid deposits is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIBRILLARY AND IMMUNOTACTOID DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrillary glomerulonephritis and immunotactoid glomerulopathy are uncommon disorders, being present in 0.5 to 1 percent of native renal biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Most investigators feel that, based upon histologic features and clinical associations, fibrillary glomerulonephritis and immunotactoid glomerulopathy are separate disorders, with fibrillary glomerulonephritis accounting for approximately 85 to 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,5,8\">",
"     3,5,8",
"    </a>",
"    ]. However, some believe that they are pathogenetically related, with no compelling histologic or clinical reasons to separate the two. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'One or two disorders?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathology and pathogenesis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Fibrillary glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of fibrillary glomerulonephritis is established by renal biopsy, with the pathognomonic changes seen on electron microscopy.",
"   </p>",
"   <p>",
"    The light microscopic findings are nondiagnostic and variable, showing patterns that may be seen with other glomerulonephritides [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These include focal mesangial or diffuse proliferative or membranoproliferative glomerulonephritis, with or without crescent formation, a membranous pattern, and mesangial expansion with amorphous material that may be suggestive of amyloidosis or light chain deposition disease (",
"    <a class=\"graphic graphic_picture graphicRef74384 \" href=\"UTD.htm?31/0/31753\">",
"     picture 1",
"    </a>",
"    ). In a study of 66 patients, the most common histologic patterns were",
"    <span class=\"nowrap\">",
"     mesangioproliferative/sclerosing",
"    </span>",
"    glomerulonephritis and membranoproliferative glomerulonephritis, which were observed in 71 percent and 15 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunofluorescence microscopy is positive for IgG, C3, and both kappa and lambda (ie, polyclonal) light chains [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/1,4,10,11\">",
"     1,4,10,11",
"    </a>",
"    ]. There may be selective deposition of some IgG subclasses. In a single center series of 67 patients, 61 of whom had fibrillary glomerulonephritis, immunofluorescence microscopy in 19 cases found oligotypic deposits (all with IgG1 and IgG4 subclasses) in 15, with the remaining four having monotypic deposits (two IgG1 and two IgG4) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3\">",
"     3",
"    </a>",
"    ]. IgA, IgM and C1q deposition may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]. The fibrillary deposits may be so extensive that the IgG deposition may be linear, similar to that seen in anti-GBM antibody disease (",
"    <a class=\"graphic graphic_picture graphicRef61547 \" href=\"UTD.htm?32/55/33649\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathognomonic histologic findings are seen on electron microscopy, which shows random fibrillar deposits in the mesangium and glomerular capillary walls that are clearly distinct from those seen in amyloidosis (",
"    <a class=\"graphic graphic_picture graphicRef82244 \" href=\"UTD.htm?20/46/21225\">",
"     picture 3",
"    </a>",
"    ). The fibrils are larger than those in amyloidosis (16 to 24 nm in fibrillary glomerulonephritis and 30 to 50 nm in immunotactoid glomerulopathy versus 10 nm in diameter in amyloidosis). In addition to being smaller, the fibrils in fibrillary glomerulonephritis (",
"    <a class=\"graphic graphic_picture graphicRef72813 \" href=\"UTD.htm?5/47/5881\">",
"     picture 4",
"    </a>",
"    ) are more randomly arranged than those observed in immunotactoid glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,9\">",
"     3,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to amyloid fibrils, the fibrils in fibrillary glomerulonephritis do not stain with Congo red or thioflavine-T or with antibodies to a specific light chain (either lambda or kappa) or to serum amyloid A [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. It is likely that many cases previously diagnosed as \"Congo red-negative\" amyloidosis were in fact fibrillary glomerulonephritis.",
"   </p>",
"   <p>",
"    Fibrillary glomerulonephritis was initially considered to be an idiopathic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3\">",
"     3",
"    </a>",
"    ]. However, approximately one-third of patients have a history of malignancy, monoclonal gammopathy, or autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Immunotactoid glomerulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotactoid glomerulopathy, in contrast to fibrillary glomerulonephritis, is characterized by the formation of microtubules on electron microscopy. In addition, these microtubules are much larger than the fibrils in fibrillary glomerulonephritis (30 to 50 versus 16 to 24 nm in diameter) (",
"    <a class=\"graphic graphic_picture graphicRef72813 \" href=\"UTD.htm?5/47/5881\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/2,6,8,9\">",
"     2,6,8,9",
"    </a>",
"    ]. Many patients have either a circulating paraprotein or monoclonal immunoglobulin deposition in the glomeruli on immunofluorescence microscopy with a restricted light chain, either kappa or lambda (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,6,8,11\">",
"     3,6,8,11",
"    </a>",
"    ]. Some authors call this disorder glomerulonephritis with organized monoclonal microtubular immunoglobulin deposits (GOMMID) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 14 patients with immunotactoid glomerulopathy, glomerular deposits were monotypic in 13 patients who also had a",
"    <strong>",
"     monoclonal",
"    </strong>",
"    immunoglobulin of the same isotype in the serum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the cytoplasm of lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, a lymphoproliferative disease was observed in seven patients. By comparison, none of nine patients with fibrillary glomerulonephritis had a paraprotein or a lymphoproliferative disorder, while eight of the nine patients had",
"    <strong>",
"     polyclonal",
"    </strong>",
"    immunoglobulin glomerular deposits.",
"   </p>",
"   <p>",
"    Thus, a careful search for a lymphoproliferative disease should be part of the routine evaluation of patients with immunotactoid glomerulopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     One or two disorders?",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, most experts feel that fibrillary glomerulonephritis and immunotactoid glomerulopathy are separate disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/2,3,8,11,12\">",
"     2,3,8,11,12",
"    </a>",
"    ]. However, some believe they are pathogenetically related [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the usual histologic distinctions, some features may not be unique to fibrillary or immunotactoid disease. As an example, there is some overlap in the size of the fibrils in patients thought to have one or the other disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, the presence of hollow electron-lucent microtubule fibrils has been described in both forms and it may be difficult to distinguish between these disorders clinically.",
"   </p>",
"   <p>",
"    The fibril or microtubule deposition in these conditions is almost always limited to the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/7\">",
"     7",
"    </a>",
"    ]. There are, however, several observations which are consistent with a",
"    <strong>",
"     systemic",
"    </strong>",
"    rather than an intrarenal disease among patients with fibrillary glomerulonephritis and immunotactoid glomerulopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both disorders can recur in the renal transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4,5,8,13,14\">",
"       4,5,8,13,14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'End-stage renal disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Two patients with extrarenal deposits have been described: one with fibril deposition in the alveolar capillaries, leading to fatal pulmonary hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/15\">",
"       15",
"      </a>",
"      ]; and one with immunotactoid deposition in the bone marrow [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting clinical features of fibrillary glomerulonephritis and immunotactoid glomerulopathy are similar to those in other forms of glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/2,4,5,7,9\">",
"     2,4,5,7,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H2#H2\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Clinical patterns of glomerular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest reported experience described the clinical features in 186 patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 90 percent of patients had fibrillary glomerulonephritis but the clinical findings were similar in both disorders.",
"   </p>",
"   <p>",
"    The following findings were noted at presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematuria in 70 percent",
"     </li>",
"     <li>",
"      Proteinuria in 100 percent with nephrotic syndrome (protein excretion &ge;3.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      in 70 to 75 percent",
"     </li>",
"     <li>",
"      Renal insufficiency (serum creatinine &ge;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      in 50 to 55 percent",
"     </li>",
"     <li>",
"      Hypertension in 65 to 70 percent",
"     </li>",
"     <li>",
"      Age range 10 to 81 years (mean 50 years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194907505\">",
"    <span class=\"h3\">",
"     Associated diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of fibrillary glomerulonephritis and immunotactoid glomerulopathy are idiopathic. However, both disorders have been associated with malignancy, monoclonal gammopathy, and autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3-5,11,17\">",
"     3-5,11,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which these associated disorders occur was illustrated in a report of 66 patients with fibrillary glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifteen patients (23 percent) had an associated malignancy, which was diagnosed 15 years before to 10 years after the onset of renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"       4",
"      </a>",
"      ]. Seventeen of the 25 malignancies were due to multiple myeloma or leukemia.",
"     </li>",
"     <li>",
"      Eleven patients (17 percent) had a monoclonal gammopathy, which is similar to the 15 percent incidence reported in another study [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ten patients (15 percent) had autoimmune disorders (most often Crohn's disease, lupus, Graves' disease, and immune thrombocytopenia [ITP]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, immunotactoid glomerulopathy is more frequently associated with chronic lymphocytic leukemia and related B cell lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,5,11,17\">",
"     3,5,11,17",
"    </a>",
"    ]. The association with lymphoproliferative neoplasia is most pronounced in patients who have a serum or urine monoclonal paraprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/5,11,18\">",
"     5,11,18",
"    </a>",
"    ]. In a study of 186 patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy, the 12 patients with immunotactoid glomerulopathy had a much higher rate or a paraprotein with or without a lymphoproliferative neoplasia than patients with fibrillary glomerulonephritis (33 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/5\">",
"     5",
"    </a>",
"    ]. Other reported associated diseases in immunotactoid glomerulopathy include cryoglobulinemia and lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both fibrillary glomerulonephritis and immunotactoid glomerulopathy have been associated with hepatitis C virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4,19\">",
"     4,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110153761\">",
"    <span class=\"h4\">",
"     Screening for associated diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above observations, patients with both fibrillary glomerulonephritis and immunotactoid glomerulopathy should be screened for malignancy, monoclonal gammopathy, autoimmune disease, and hepatitis C virus infection. The temporal relationship with these diseases is variable. As an example, malignancy may precede, be concomitant with, or follow the diagnosis by many years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, ongoing monitoring is warranted in these patients. Thus, we perform the following tests at the time the renal disease is diagnosed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with differential (should be repeated at least annually)",
"     </li>",
"     <li>",
"      Serum immunofixation and serum free light chains (should be repeated at least annually)",
"     </li>",
"     <li>",
"      Antibodies against hepatitis C",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 to 50 percent of reported patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy develop end-stage renal disease (ESRD) within two to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/1-4,6,7,9\">",
"     1-4,6,7,9",
"    </a>",
"    ]. In a single center series that included 61 patients with fibrillary glomerulonephritis, the mean time to ESRD varied according to the histologic findings on light microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      7 months with diffuse sclerosing glomerulonephritis",
"     </li>",
"     <li>",
"      20 months with diffuse proliferative glomerulonephritis",
"     </li>",
"     <li>",
"      44 months with membranoproliferative glomerulonephritis",
"     </li>",
"     <li>",
"      80 months with",
"      <span class=\"nowrap\">",
"       mesangioproliferative/sclerosing",
"      </span>",
"      disease",
"     </li>",
"     <li>",
"      87 months with membranous glomerulonephritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in another single center series of 66 patients with fibrillary glomerulonephritis, including a shorter time to ESRD in patients with membranoproliferative glomerulonephritis compared with mesangial",
"    <span class=\"nowrap\">",
"     proliferative/sclerosing",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the distinction between mesangioproliferative and membranoproliferative glomerulonephritis may be related to the timing of the renal biopsy, rather than differences in pathogenesis, with mesangial proliferation representing an early form of membranoproliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the prognosis may be better in immunotactoid glomerulopathy than in fibrillary glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a study that combined the clinical characteristics of 25 patients evaluated at one center with those of 161 patients described in various studies published between 1977 to 1994 found",
"    <strong>",
"     little, if any, difference",
"    </strong>",
"    in clinical outcomes in these two disorders (",
"    <a class=\"graphic graphic_table graphicRef54858 \" href=\"UTD.htm?41/62/42988\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/5,18\">",
"     5,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment and renal prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials upon which to base treatment recommendations for patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy. In patients with idiopathic disease, treatment is generally determined by the severity of kidney dysfunction.",
"   </p>",
"   <p>",
"    In the largest reported follow-up study of 61 patients with fibrillary glomerulonephritis who were followed and treated conservatively with angiotensin inhibition for a mean of 52 months, 3 patients had complete remission, five had partial remission, 26 had progressive renal disease, and 27 (44 percent) developed end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]. Four of the eight patients with complete or partial remission had mild disease at the time of renal biopsy as defined by a normal estimated glomerular filtration rate and non-nephrotic range proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110158364\">",
"    <span class=\"h3\">",
"     Nonimmunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a normal estimated glomerular filtration rate and non-nephrotic range proteinuria are usually treated conservatively with angiotensin blockade in order to control blood pressure, reduce protein excretion, and slow the progression of the disease. These general issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H6#H6\">",
"     \"Assessment of kidney function\", section on 'Estimation of GFR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the follow-up study cited above of 61 patients with fibrillary glomerulonephritis who were followed for a mean of 52 months, 16 patients were treated with angiotensin blockade alone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]. Two of these patients had complete remission, two had partial remission, eight had progressive kidney disease, and four progressed to end-stage renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110158390\">",
"    <span class=\"h3\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy with glucocorticoids with or without other agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and rapamycin) has been reported in uncontrolled studies with limited and inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3,4,9,22\">",
"     3,4,9,22",
"    </a>",
"    ]. There have been",
"    <strong>",
"     no",
"    </strong>",
"    randomized trials.",
"   </p>",
"   <p>",
"    The following observations are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study cited above, 29 patients with fibrillary glomerulonephritis were treated with various immunosuppressive regimens, with the following results: three achieved a partial remission, 11 had progressive kidney disease, and 15 developed end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"       4",
"      </a>",
"      ]. There was",
"      <strong>",
"       no",
"      </strong>",
"      evidence of efficacy in the patients who were treated with glucocorticoids alone as all had progressive disease. The three partial remissions were seen in the 16 patients who were treated with glucocorticoids and one or more additional agents.",
"     </li>",
"     <li>",
"      Similar findings were found in another report in which 16 patients with fibrillary glomerulonephritis were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cytotoxic agents (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/22\">",
"       22",
"      </a>",
"      ]. Fourteen showed no response, while two had partial remission of proteinuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has been associated with complete or partial remission of proteinuria in some cases of fibrillary glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]. Most of the rituximab-treated patients who benefited had proliferative glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Rituximab also appeared to be effective in a case report of recurrent immunotactoid glomerulopathy in the transplant that had not responded to conventional immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'End-stage renal disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients presenting with a rapidly progressive glomerulonephritis and crescents on renal biopsy are treated with high dose glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as used in other forms of crescentic glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that patients with idiopathic fibrillary glomerulonephritis or immunotactoid glomerulopathy should be treated according to the findings on light microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/3\">",
"     3",
"    </a>",
"    ]. The rationale for such an approach is based upon the observation that patients with a membranoproliferative pattern of injury progress faster to end-stage renal disease than patients with a mesangioproliferative pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the mesangioproliferative pattern may represent an earlier stage of disease rather than milder disease. Consistent with this hypothesis is the observation that, when renal histology was stratified by immunosuppressive therapy, there was no effect of immunosuppression on the rate of progression to end-stage renal disease. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Course'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194906821\">",
"    <span class=\"h3\">",
"     Treat the underlying disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, malignancy, monoclonal gammopathy, and autoimmune diseases occur in more than one-third of patients with fibrillary glomerulonephritis, and chronic lymphocytic leukemia and related B cell lymphomas have been associated with immunotactoid glomerulopathy. Thus, a careful search for a secondary cause should be part of the routine evaluation of these disorders. Ongoing screening may be warranted since these disorders can first be detected",
"    <strong>",
"     after",
"    </strong>",
"    the diagnosis of the renal disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H110153761\">",
"     'Screening for associated diseases'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Effective therapy directed at the underlying disorder appears to have a beneficial effect on the renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/11,17,24,28\">",
"     11,17,24,28",
"    </a>",
"    ]. The potential benefit of such an approach was illustrated in a study of 12 patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who had nephrotic syndrome and a lymphoproliferative disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/11\">",
"     11",
"    </a>",
"    ]. Complete or partial remission of the nephrotic syndrome occurred in 10 of the 12 patients after the initiation of chemotherapy, with a parallel improvement in the hematologic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis or renal transplantation can be performed in patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy who progress to end-stage renal disease. With renal transplantation, recurrent disease can develop in the allograft in both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4,5,13,14,18\">",
"     4,5,13,14,18",
"    </a>",
"    ], but the rate of progression is usually slower than in the native kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/5,13,14,18,29\">",
"     5,13,14,18,29",
"    </a>",
"    ]. The rate of recurrence appears be higher in patients who have a monoclonal gammopathy, which occurs in both disorders. (See",
"    <a class=\"local\" href=\"#H194907505\">",
"     'Associated diseases'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Specific data on the rate of recurrence in fibrillary glomerulonephritis are limited to relatively small numbers of patients. The following findings are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated 14 patients with fibrillary glomerulonephritis who underwent renal transplantation, five of whom developed biopsy-proven recurrent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"       4",
"      </a>",
"      ]. Two patients underwent repeat renal transplantation: one lost the graft again because of recurrent disease and one had no recurrence.",
"     </li>",
"     <li>",
"      An earlier study from the same institution included 12 patients (11 of whom were in the later report): five had fibrillary glomerulonephritis and seven had monoclonal gammopathy with fibrillary deposits [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/14\">",
"       14",
"      </a>",
"      ]. Recurrent disease was not seen in any of the patients with fibrillary glomerulonephritis but developed in five allografts in four patients with a monoclonal gammopathy, resulting in graft loss in three.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on recurrent disease in the transplant are limited in immunotactoid glomerulopathy since, as noted above, it is a much less common disease than fibrillary glomerulonephritis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Fibrillary and immunotactoid disease'",
"    </a>",
"    above.) In a report of two patients who underwent renal transplantation plus two others in case reports, two developed recurrent disease at two to six year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/13\">",
"     13",
"    </a>",
"    ]. In other case reports, more aggressive immunosuppressive therapy (including plasma exchange, pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    pulses rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/25\">",
"     25",
"    </a>",
"    ] or the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/30\">",
"     30",
"    </a>",
"    ], appeared to be beneficial.",
"   </p>",
"   <p>",
"    In summary, renal transplantation is a reasonable therapeutic option for patients with fibrillary glomerulonephritis who develop end-stage renal disease. However, the role of transplantation is controversial in patients with immunotactoid glomerulopathy who have an underlying a monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER FIBRILLARY DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike fibrillary glomerulonephritis and immunotactoid glomerulopathy, other nonamyloid fibrillary glomerular diseases have been described in which staining for immunoglobulins is negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fibronectin glomerulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibronectin glomerulopathy is an autosomal dominant disorder associated with massive deposition of fibronectin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31221?source=see_link\">",
"     \"Fibronectin glomerulopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Collagenofibrotic glomerulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collagenofibrotic glomerulopathy, also called collagen type III glomerulopathy, is a rare disorder that is characterized by the massive accumulation of atypical type III collagen fibrils in the mesangium and subendothelial space [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_picture graphicRef86281 \" href=\"UTD.htm?35/27/36276\">",
"     picture 5",
"    </a>",
"    ). Light microscopy reveals findings consistent with membranoproliferative glomerulonephritis, including a double-contour appearance of the peripheral capillary walls. A definitive diagnosis requires electron microscopy, which reveals fibers with a transverse band structure and a distinctive periodicity of approximately 60 nm [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/31\">",
"     31",
"    </a>",
"    ]. This is the same as that observed with type III collagen.",
"   </p>",
"   <p>",
"    Controversy exists as to whether collagenofibrotic glomerulopathy is a primary disease of the kidney or a systemic process. Marked elevations in serum type III procollagen peptide levels are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/31\">",
"     31",
"    </a>",
"    ]. Some cases have been described in families, suggesting an autosomal recessive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected patients typically present with proteinuria and edema, with frequent progression to end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/31\">",
"     31",
"    </a>",
"    ]. There is no specific therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nail-patella syndrome and hereditary multiple exostoses syndrome (also called hereditary multiple osteochondromas syndrome) may develop nephrotic syndrome associated with glomerular fibrillar collagen deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1973?source=see_link&amp;anchor=H5#H5\">",
"     \"Nail-patella syndrome\", section on 'Renal manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link&amp;anchor=H9#H9\">",
"     \"Chondrosarcoma\", section on 'Peripheral chondrosarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glomerular disease associated with fibrillar deposits primarily includes amyloidosis, fibrillary glomerulonephritis and immunotactoid glomerulopathy. Other rare glomerular diseases associated with fibrillar deposits include fibronectin glomerulopathy and collagenofibrotic glomerulopathy. Whereas the overwhelming majority of amyloid fibrils are typically Congo-red positive, very early amyloidosis can be Congo-red negative. Similarly, cases of heavy chain amyloidosis can be Congo-red negative, but precise diagnosis can be achieved by mass spectrometry-based proteomic diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33064/abstract/34\">",
"       34",
"      </a>",
"      ]. All other forms of fibrillary deposition disease are characterized by Congo-red negative fibrils. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Other fibrillary disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibrillary glomerulonephritis and immunotactoid glomerulopathy can be distinguished from each other by electron microscopy; the fibrils that characterize fibrillary glomerulonephritis are smaller and typically randomly oriented as opposed to the larger and often organized fibrils of immunotactoid glomerulopathy. The light microscopic findings for both are variable and include focal or diffuse glomerulonephritis with or without crescent formation, a membranous pattern, a membranoproliferative and an amyloid-like pattern. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with both fibrillary and immunotactoid disease present with significant proteinuria that is often in the nephrotic range; other findings include microscopic hematuria, hypertension, and renal insufficiency that may progress rapidly. Approximately half of the patients develop end-stage renal disease within two to six years. Both disorders can recur in the renal transplant. Recurrence is especially likely in patients with monoclonal gammopathy and fibrillary deposits on renal biopsy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Course'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'One or two disorders?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunotactoid glomerulopathy is far less common than fibrillary glomerulonephritis. Some patients with both fibrillary glomerulonephritis and immunotactoid glomerulopathy have or will develop a lymphoproliferative disorder or other malignancy. A careful search for a lymphoproliferative disease and other malignancies should be part of the routine evaluation of patients with fibrillary and immunotactoid glomerulopathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunotactoid glomerulopathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibrillary and immunotactoid glomerular disease are difficult to treat and there are no controlled trials to guide therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment and renal prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with fibrillary glomerulonephritis or immunotactoid glomerulopathy associated with chronic lymphocytic leukemia (CLL), related B cell lymphomas, or other disorders may respond to therapy directed at the underlying disorder. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment and renal prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis or renal transplantation can be performed in those patients who progress to end-stage renal disease. Although recurrent disease in the graft is common, the rate of progression in idiopathic cases is generally slower than in the native kidney. However, for patients with a monoclonal gammopathy and fibrillary deposits, kidney transplant is controversial. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'End-stage renal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/1\">",
"      Alpers CE, Rennke HG, Hopper J Jr, Biava CG. Fibrillary glomerulonephritis: an entity with unusual immunofluorescence features. Kidney Int 1987; 31:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/2\">",
"      Iskandar SS, Falk RJ, Jennette JC. Clinical and pathologic features of fibrillary glomerulonephritis. Kidney Int 1992; 42:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/3\">",
"      Rosenstock JL, Markowitz GS, Valeri AM, et al. Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic features. Kidney Int 2003; 63:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/4\">",
"      Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011; 6:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/5\">",
"      Pronovost PH, Brady HR, Gunning ME, et al. Clinical features, predictors of disease progression and results of renal transplantation in fibrillary/immunotactoid glomerulopathy. Nephrol Dial Transplant 1996; 11:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/6\">",
"      Fogo A, Qureshi N, Horn RG. Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 1993; 22:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/7\">",
"      Korbet SM, Schwartz MM, Lewis EJ. Immunotactoid glomerulopathy. Am J Kidney Dis 1991; 17:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/8\">",
"      Alpers CE. Immunotactoid (microtubular) glomerulopathy: an entity distinct from fibrillary glomerulonephritis? Am J Kidney Dis 1992; 19:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/9\">",
"      Schwartz MM, Korbet SM, Lewis EJ. Immunotactoid glomerulopathy. J Am Soc Nephrol 2002; 13:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/10\">",
"      Yang GC, Nieto R, Stachura I, Gallo GR. Ultrastructural immunohistochemical localization of polyclonal IgG, C3, and amyloid P component on the congo red-negative amyloid-like fibrils of fibrillary glomerulopathy. Am J Pathol 1992; 141:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/11\">",
"      Bridoux F, Hugue V, Coldefy O, et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002; 62:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/12\">",
"      Nickeleit V, Moll S, Schmid M, Mihatsch MJ. Nephrotic syndrome in an adult: the ongoing saga of fibrils versus microtubules. Am J Kidney Dis 1999; 34:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/13\">",
"      Korbet SM, Rosenberg BF, Schwartz MM, Lewis EJ. Course of renal transplantation in immunotactoid glomerulopathy. Am J Med 1990; 89:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/14\">",
"      Czarnecki PG, Lager DJ, Leung N, et al. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int 2009; 75:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/15\">",
"      Masson RG, Rennke HG, Gottlieb MN. Pulmonary hemorrhage in a patient with fibrillary glomerulonephritis. N Engl J Med 1992; 326:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/16\">",
"      Wallner M, Prischl FC, H&ouml;bling W, et al. Immunotactoid glomerulopathy with extrarenal deposits in the bone, and chronic cholestatic liver disease. Nephrol Dial Transplant 1996; 11:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/17\">",
"      Moulin B, Ronco PM, Mougenot B, et al. Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 1992; 42:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/18\">",
"      Brady HR. Fibrillary glomerulopathy. Kidney Int 1998; 53:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/19\">",
"      Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/20\">",
"      Bj&oslash;rneklett R, Vikse BE, Svarstad E, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/21\">",
"      Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/22\">",
"      D'Agati, V, Sacchi, G, Truong, L, et al. Fibrillary glomerulopathy: Defining the disease spectrum. J Am Soc Nephrol 1991; 2:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/23\">",
"      Collins M, Navaneethan SD, Chung M, et al. Rituximab treatment of fibrillary glomerulonephritis. Am J Kidney Dis 2008; 52:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/24\">",
"      Bhat P, Weiss S, Appel GB, Radhakrishnan J. Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis 2007; 50:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/25\">",
"      Carles X, Rostaing L, Modesto A, et al. Successful treatment of recurrence of immunotactoid glomerulopathy in a kidney allograft recipient. Nephrol Dial Transplant 2000; 15:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/26\">",
"      Mahajan S, Kalra V, Dinda AK, et al. Fibrillary glomerulonephritis presenting as rapidly progressive renal failure in a young female: a case report. Int Urol Nephrol 2005; 37:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/27\">",
"      Sharma P, Kuperman M, Racusen L, Geetha D. Fibrillary glomerulonephritis presenting as rapidly progressive glomerulonephritis. Am J Kidney Dis 2012; 60:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/28\">",
"      Vilayur E, Trevillian P, Walsh M. Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol 2009; 5:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/29\">",
"      Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012; 307:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/30\">",
"      Sathyan S, Khan FN, Ranga KV. A case of recurrent immunotactoid glomerulopathy in an allograft treated with rituximab. Transplant Proc 2009; 41:3953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/31\">",
"      Alchi B, Nishi S, Narita I, Gejyo F. Collagenofibrotic glomerulopathy: clinicopathologic overview of a rare glomerular disease. Am J Kidney Dis 2007; 49:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/32\">",
"      Chen N, Pan X, Xu Y, et al. Two brothers in one Chinese family with collagen type III glomerulopathy. Am J Kidney Dis 2007; 50:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/33\">",
"      Roberts IS, Gleadle JM. Familial nephropathy and multiple exostoses with exostosin-1 (EXT1) gene mutation. J Am Soc Nephrol 2008; 19:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33064/abstract/34\">",
"      Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5:2180.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3115 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33064=[""].join("\n");
var outline_f32_18_33064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIBRILLARY AND IMMUNOTACTOID DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Fibrillary glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Immunotactoid glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - One or two disorders?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194907505\">",
"      - Associated diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110153761\">",
"      Screening for associated diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment and renal prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110158364\">",
"      - Nonimmunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H110158390\">",
"      - Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194906821\">",
"      - Treat the underlying disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER FIBRILLARY DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fibronectin glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Collagenofibrotic glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3115|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/0/31753\" title=\"picture 1\">",
"      Fibrillary glomerulonephritis light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/55/33649\" title=\"picture 2\">",
"      Fibrillary glomerulonephritis IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/46/21225\" title=\"picture 3\">",
"      Fibrillary glomerulonephritis EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/47/5881\" title=\"picture 4\">",
"      Fibrillary vs immunotactoid glomerulonephritis EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/27/36276\" title=\"picture 5\">",
"      Collagen type III glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/62/42988\" title=\"table 1\">",
"      Clinical features fibrillary glomerulonephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31221?source=related_link\">",
"      Fibronectin glomerulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1973?source=related_link\">",
"      Nail-patella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33065="Initial treatment of peripheral T cell lymphoma";
var content_f32_18_33065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of peripheral T cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33065/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33065/contributors\">",
"     Eric Jacobsen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33065/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33065/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33065/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/18/33065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults. Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS)",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type (ALCL)",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma (AITL)",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Adult T cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"     <li>",
"      Mycosis",
"      <span class=\"nowrap\">",
"       fungoides/S&eacute;zary",
"      </span>",
"      syndrome",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of the majority of noncutaneous PTCL subtypes will be reviewed here. The treatment of the following subtypes is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult T cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"       \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H20#H20\">",
"       \"Management of gastrointestinal lymphomas\", section on 'Enteropathy-associated T cell intestinal lymphoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mycosis",
"      <span class=\"nowrap\">",
"       fungoides/S&eacute;zary",
"      </span>",
"      syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"       \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=see_link\">",
"       \"Treatment of extranodal NK/T cell lymphoma, nasal type\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical presentation, pathologic features, diagnosis, and prognosis of PTCLs are presented elsewhere, as is the treatment of relapsed or refractory PTCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of patients with NHL must establish the precise histologic subtype, the extent and sites of disease (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ), and the performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"UTD.htm?43/16/44300\">",
"     table 2A-B",
"    </a>",
"    ) of the patient. General approaches to the diagnostic work-up and staging of NHL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis has been definitively established, the pretreatment evaluation determines both the bulk of disease and the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with PTCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), hepatitis B, HIV, and uric acid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspiration and biopsy.",
"     </li>",
"     <li>",
"      A contrast-enhanced computed tomography (CT) scan of the chest, abdomen and pelvis. This study provides critical information on the measurement of disease prior to treatment and aids in staging [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/1\">",
"       1",
"      </a>",
"      ]. Most cases of PTCL are FDG-avid. When available, we obtain a combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scan at diagnosis to serve as a baseline for comparison after therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed if anthracyclines are used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women of childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTCL is a heterogeneous group of T cell lymphomas and survival depends, at least partially, upon the subtype identified. In general, without treatment the survival of patients with PTCL is measured in months. With combination chemotherapy, five-year overall survival rates may be as high as 74 and 49 percent among patients with a low (ie, zero to 1) or low intermediate (ie, 2) score on the International Prognostic Index (IPI), respectively (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/2\">",
"     2",
"    </a>",
"    ]. However, such low risk patients are uncommon and the five-year survival rates after combination chemotherapy are 21 and 6 percent for the more common patient with high intermediate (ie, 3) or high (ie, 4 to 5) IPI scores, respectively.",
"   </p>",
"   <p>",
"    Historically, patients with PTCL have been included in trials of chemotherapy regimens for patients with aggressive NHL. However, the rarity and heterogeneity of patients with PTCL have limited the ability to make conclusions regarding treatment based upon subset analyses of these trials. It is clear that patients with T cell NHL have inferior rates of response to chemotherapy, progression-free survival (PFS), and overall survival than patients with B cell NHL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall response rates with CHOP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) chemotherapy for T cell NHL range from 50 to 70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/3\">",
"       3",
"      </a>",
"      ]. In comparison, response rates with CHOP or CHOP plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in B cell NHL are generally 80 to 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The median PFS in PTCL following CHOP chemotherapy is 12 to 14 months with approximately 30 percent of patients being alive and free of disease five years after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/5\">",
"       5",
"      </a>",
"      ]. By way of comparison, the PFS at five years in diffuse large B cell lymphoma is 54 percent with approximately 60 percent of patients being long-term disease-free survivors [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The poor outcomes with conventional chemotherapy have generated interest in more aggressive strategies such as the use of autologous HCT or radiation therapy as consolidation. The role of consolidation therapy in PTCL is controversial and its use varies depending upon the lymphoma subtype and the patient's IPI score. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Consolidation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no general consensus regarding the preferred induction chemotherapy for PTCL, and patients should be encouraged to participate in clinical trials whenever possible. Most of the treatment regimens that have been studied combine an anthracycline with an alkylating agent. Examples of regimens most commonly considered for the treatment of patients with PTCL not enrolled in clinical trials include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CHOP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef81762 \" href=\"UTD.htm?8/46/8942\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      EPOCH (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been few prospective trials comparing chemotherapy regimens in this population. CHOP has become the most frequently employed regimen for PTCL largely based on the extrapolation of studies in aggressive B cell NHL. Patients with PTCL comprised a minority of the patients in randomized trials comparing CHOP chemotherapy with many other anthracycline-based regimens in aggressive NHL. When compared with CHOP, more aggressive regimens offered no improvement in remission rate, disease-free survival, or overall survival and were associated with increased toxicity. These studies are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Choice of chemotherapy regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized phase III trial comparing CHOP chemotherapy with a more intensive chemotherapy regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    alternating with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) in 88 patients with newly diagnosed PTCL reported no difference in event-free survival at two years, but greater toxicity with the more intensive regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, a single institution retrospective analysis of 135 patients with PTCL reported no improvement in three-year overall survival rates when CHOP was compared with more intensive regimens such as HyperCVAD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , doxorubicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients treated with intensive regimens had more early deaths due to treatment toxicity.",
"   </p>",
"   <p>",
"    While highly intensive chemotherapy regimens do not appear to improve outcomes, data suggest that adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    to standard dose CHOP for younger patients with PTCL improves event-free survival. A post-hoc analysis evaluated outcomes from 320 patients with PTCL treated on prospective trials with six to eight cycles of CHOP or CHOP plus etoposide (CHOEP) and followed for a median of 44 months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/3\">",
"     3",
"    </a>",
"    ]. The majority of patients had one of the following four entities: ALK-positive ALCL (24 percent), ALK-negative ALCL (35 percent), PTCL, NOS (22 percent), or AITL (9 percent). For patients younger than age 60 who had a normal LDH at diagnosis, CHOEP resulted in a significantly higher rate of event-free survival at three years when compared with CHOP (75 versus 51 percent, respectively). The magnitude of difference in event-free survival was largest for patients with ALK-positive ALCL (91 versus 57 percent) and was smaller when these patients were excluded from the analysis (61 versus 48 percent). This benefit was not seen in patients over the age of 60 years. There was no significant difference in overall survival at three years.",
"   </p>",
"   <p>",
"    For patients with newly diagnosed PTCL who are not candidates for clinical trials or do not wish to participate in clinical trials, we suggest induction chemotherapy with a CHOP-based regimen rather than more intensive induction regimens such as EPOCH or HyperCVAD. For patients younger than 60 years, we suggest the use of CHOEP rather than CHOP. This preference places a high importance on the improved event-free survival seen with CHOEP with the understanding that adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    will increase toxicity. Patients over the age of 60 years are generally treated with CHOP in order to avoid the increased toxicity. With either of these regimens, we administer CHOP every three weeks (",
"    <a class=\"graphic graphic_table graphicRef66136 \" href=\"UTD.htm?0/54/876\">",
"     table 5",
"    </a>",
"    ). For CHOEP, intravenous etoposide (100",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    is administered on days 1 through 3 of each 21 day cycle in addition to standard CHOP. Alternatively, standard CHOP may be administered with intravenous etoposide (100",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    on day 1 followed by oral etoposide (200",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    on days 2 and 3 of each 21-day cycle. The higher oral dose of etoposide is necessary due to poor bioavailability with oral administration.",
"   </p>",
"   <p>",
"    Depending on the histology and patient population studied, overall response rates with CHOP are between 50 and 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    side effect is granulocytopenia (approximately 60 percent). Other common side effects are generally mild to moderate alopecia, nausea, vomiting, and infusion related reactions. There is a 1 percent treatment-related mortality rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONSOLIDATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The poor outcomes in certain subgroups of patients with PTCL after conventional chemotherapy alone have generated interest in the use of hematopoietic cell transplantation (HCT) or radiation therapy as consolidation therapy. The role of consolidation therapy in PTCL is controversial. However, there is a general consensus that HCT is",
"    <strong>",
"     not",
"    </strong>",
"    indicated after the attainment of a first complete remission in the following two subgroups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ALK positive anaplastic large cell lymphoma (ALCL). Such patients have five-year overall survival rates ranging from 70 to 93 percent after anthracycline-based chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/8-12\">",
"       8-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with localized PTCL, NOS and a low or low intermediate IPI score (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 3",
"      </a>",
"      ). Five-year overall survival rates are 74 and 49 percent among patients with a low (ie, zero to 1) or low intermediate (ie, 2) IPI score, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PTCL patients who do not fit into these two categories have five-year overall survival rates of 20 percent or less after combination chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/2\">",
"     2",
"    </a>",
"    ]. Such patients should be considered for consolidation therapy. The choice among autologous HCT, radiation therapy, or a combination of the two depends upon the patient's candidacy for HCT and the extent of initial disease. Consolidation radiation therapy is largely reserved for use in patients with localized (stage I or II) PTCL. Autologous HCT, preferably given in the context of a clinical trial, is generally offered in addition to radiation for patients initially presenting with localized disease and an intermediate or high IPI. Autologous HCT, administered without radiation therapy, is offered to those who had extensive disease at the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Autologous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (auto-HCT) has been evaluated for the treatment of PTCL in retrospective analyses and small prospective trials enrolling a very select group of patients with good performance status. Overall, auto-HCT appears to be most beneficial for patients in first complete remission (CR) relative to second or subsequent CR or partial remission (PR) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. With auto-HCT in first CR, overall survival (OS) rates may be as high as 85 percent at three years and 30 percent at five years post auto-HCT, but vary depending upon the lymphoma subtype and International Prognostic Index (IPI) score (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As mentioned above, our general approach to the use of auto-HCT for consolidation after CR is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We do not routinely perform auto-HCT for patients with PTCL, NOS in first CR who have localized disease and a low or low intermediate IPI score (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 3",
"      </a>",
"      ). This is principally because such patients demonstrate five-year OS rates ranging from 50 to 75 percent after chemotherapy plus consolidation radiation therapy.",
"     </li>",
"     <li>",
"      For patients who are candidates for auto-HCT with PTCL, NOS and a high intermediate or high IPI score, we generally offer consolidation with auto-HCT in first CR since such patients demonstrate five-year OS rates of 20 percent or less after combination chemotherapy alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment-related morbidity and mortality with auto-HCT are relatively low (&le;3 percent); However, patients who undergo auto-HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the posttransplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are summaries of the largest studies investigating auto-HCT in PTCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II trial, 160 patients with previously untreated PTCL (not ALK positive ALCL) were treated with six cycles of biweekly CHOEP [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      was omitted in patients &gt;60 years. In total, 115 (72 percent) attained a complete or partial remission and proceeded with high dose chemotherapy and auto-HCT. Treatment-related mortality was 4 percent. At a median follow-up of 60.5 months, estimated rates of overall survival (OS) and progression-free survival (PFS) at five years were 51 percent (95% CI 43-59 percent) and 44 percent (95% CI 36-52 percent), respectively. On subset analysis, patients with ALK negative ALCL had significantly better outcomes when compared with the other histologic subtypes. Differences in outcomes among the other histologic subtypes did not attain statistical significance. Estimated rates of OS and PFS at five years according to histologic subtype were as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      ALK negative ALCL (31 patients) &mdash; five-year OS 70 percent, five-year PFS 61 percent",
"     </li>",
"     <li>",
"      AITL (30 patients) &mdash; five-year OS 52 percent, five-year PFS 49 percent",
"     </li>",
"     <li>",
"      EATL (21 patients) &mdash; five-year OS 48 percent, five-year PFS 38 percent",
"     </li>",
"     <li>",
"      PTCL, NOS (62 patients) &mdash; five-year OS 47 percent, five-year PFS 38 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 115 patients with PTCL who underwent high dose therapy and auto-HCT between January 1990 and December 1999 included 37 patients in first CR, 28 in second or subsequent CR, 44 in PR, and 6 with refractory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/13\">",
"       13",
"      </a>",
"      ]. As a group, the rates of five-year disease-free survival and overall survival (OS) were 60 and 56 percent, respectively. Patients transplanted in first CR had a significantly higher rate of five-year OS when compared with patients transplanted in second or subsequent CR or PR (80 versus 50 percent, respectively). No patient with refractory disease was a long-term disease-free survivor.",
"     </li>",
"     <li>",
"      Another retrospective analysis evaluated 83 patients with PTCL treated between 2000 and 2006 (32 patients with PTCL, NOS and 27 with AILD) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/17\">",
"       17",
"      </a>",
"      ]. The treatment plan consisted of four to six cycles of CHOP followed by stem cell mobilization with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      or etoposide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , cytarabine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      . Patients then underwent",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"        cyclophosphamide",
"       </a>",
"       /total",
"      </span>",
"      body irradiation conditioning followed by auto-HCT. The following outcomes were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      On intent-to-treat analysis, 55 of the 83 patients completed chemotherapy and underwent auto-HCT. The most common reason for not undergoing auto-HCT was progressive disease, which occurred in 24 patients.",
"     </li>",
"     <li>",
"      The three-year OS rate was 48 percent and varied with the PTCL prognostic index score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of smaller prospective trials have evaluated the role of auto-HCT as part of the initial treatment of PTCL [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/18-24\">",
"     18-24",
"    </a>",
"    ]. In general, these trials included heterogeneous patient populations and utilized a variety of induction and conditioning regimens. Several included patients with ALK positive ALCL, a group now known to have a superior prognosis even with treatment strategies that do not incorporate HCT. In these studies, OS rates ranged from 86 percent at three years to approximately 30 percent at 5 to 12 years post auto-HCT. Universally, these trials have tended to include a select group of younger patients. This fact, combined with the heterogeneous nature of the treatments and non-randomized design of the trials, makes it impossible to render a definitive assessment of the utility of auto-HCT in first CR for PTCL. A large, international randomized trial is desperately needed to answer this important question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Allogeneic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (allo-HCT) has also been studied in PTCL, primarily in the",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, the role of radiotherapy (RT) in managing PTCL remains undefined. In general, we offer RT in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with localized (stage I or II) disease who achieve a complete remission (CR) with chemotherapy.",
"     </li>",
"     <li>",
"      Some patients with localized disease who achieve a partial remission with chemotherapy. RT is generally offered to such patients who are not transplant (HCT) candidates. However, if a patient is a candidate for HCT, the choice to use RT in this setting is complicated by the degree of response to chemotherapy. As an example, a patient with minimal residual disease may benefit from going straight to HCT. In comparison, a patient with more substantial residual disease may be offered a second-line chemotherapy regimen prior to HCT or may be offered RT administered before or after HCT.",
"     </li>",
"     <li>",
"      Control of symptoms from localized disease in the palliative setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on the use of consolidation radiation therapy in this setting are limited to retrospective analyses and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Such analyses have noted a high rate of local relapse (30 to 40 percent at five years) with chemotherapy administered alone or with standard radiation doses used for B cell lymphomas. There has been a suggestion that higher radiation doses (eg, &ge;40 Gy) may provide better local control for patients with PTCL after CR is obtained with chemotherapy.",
"   </p>",
"   <p>",
"    Our practice is consistent with the National Comprehensive Cancer Network (NCCN) guidelines, which recommend consolidative radiotherapy in all PTCL patients with stage I or II disease who achieve remission after standard anthracycline based chemotherapy. Unlike in diffuse large B cell lymphoma where chemotherapy is abbreviated if radiation therapy is used for consolidation, patients with limited stage PTCL are treated with a full course of six to eight cycles of CHOP prior to the incorporation of radiation. This is principally because it is not known if the addition of radiation therapy allows for the truncation of CHOP chemotherapy with similar long-term outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MODIFICATION FOR SUBTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the most common PTCL histology is PTCL, NOS, there are several subtypes of PTCL with unique features that require treatment modifications. These are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaplastic large cell lymphoma,",
"    <span class=\"nowrap\">",
"     T/null",
"    </span>",
"    cell type (ALCL) has a more favorable outcome than other subtypes of PTCL, particularly in those cases expressing the ALK protein. In general, patients are treated with the same induction therapy regimens used for PTCL, NOS. However, the role of consolidation therapy is unknown and its potential benefit may be assessed based upon the tumor expression of ALK and the patient's International Prognostic Index (IPI) score (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 3",
"    </a>",
"    ). This is principally supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following treatment with an anthracycline-based chemotherapy regimen (eg, CHOP), five-year overall survival (OS) rates for patients with ALK positive ALCL have ranged from 70 to 93 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/8-12\">",
"       8-12",
"      </a>",
"      ]. In comparison, patients with ALK negative ALCL have five-year OS rates after the same treatment regimens of 15 to 49 percent.",
"     </li>",
"     <li>",
"      As with other subtypes of PTCL, survival rates of patients with ALCL vary with the IPI. In one study, patients with ALK positive ALCL and a low or low-intermediate IPI score had a five-year OS rate of 94 percent whereas those with a high-intermediate or high IPI score had a five-year OS rate of only 41 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autologous hematopoietic cell transplantation (auto-HCT) appears to provide a benefit to patients with relapsed ALK positive ALCL. In contrast, limited data suggest that auto-HCT is not as effective for ALK negative patients with relapsed disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"       \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small, uncontrolled prospective trials have evaluated the use of auto-HCT in first complete remission (CR) for patients with ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Although they have demonstrated promising results, issues of selection bias and the lack of a randomized control group limit the interpretation of these trials and the ability to generalize their results. In addition, these studies included patients with ALK positive ALCL that are known to have an excellent prognosis with induction chemotherapy alone.",
"   </p>",
"   <p>",
"    In one of the largest studies of auto-HCT for newly diagnosed ALCL, all patients achieved a CR and there were no relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/29\">",
"     29",
"    </a>",
"    ]. The event-free survival (EFS) and OS rates at five years were both 87 percent. Historical comparisons based upon the patient's age adjusted IPI suggest that the EFS and OS rates would have been expected to be 71 percent and 69 percent, respectively. However, 7 of the 15 patients were ALK positive and would have been expected to do well even without auto-HCT.",
"   </p>",
"   <p>",
"    Several reports in the literature have described successful allogeneic HCT (allo-HCT) for ALCL, but this approach has not been directly compared with auto-HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Given the toxicity of allo-HCT and the favorable outcomes obtained with conventional chemotherapy and auto-HCT, allo-HCT can only be recommended for patients with chemotherapy sensitive, relapsed disease, preferably in the setting of a clinical trial.",
"   </p>",
"   <p>",
"    For patients with ALK positive ALCL, we suggest treatment with induction chemotherapy alone followed by observation rather than induction chemotherapy followed by auto-HCT or radiation. For patients with ALK negative ALCL, we suggest the use of consolidation auto-HCT in first CR, ideally in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Angioimmunoblastic T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the preferred initial treatment of angioimmunoblastic T cell lymphoma (AITL). Treatment options include steroids, combination chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and investigational therapies. Although complete remission (CR) can be attained in many patients, relapse is frequent, with median overall survival (OS) rates ranging from 15 to 36 months with chemotherapy and of approximately four years with auto-HCT. Infection is the most common cause of death.",
"   </p>",
"   <p>",
"    Small, uncontrolled prospective trials and retrospective analyses have investigated the use of steroids, combination chemotherapy, auto-HCT, and allogeneic HCT for the treatment of AITL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, uncontrolled trial of 39 patients with AITL investigated a staged treatment approach in which patients were initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/34\">",
"       34",
"      </a>",
"      ]. Those who did not attain a CR with prednisone or those with life-threatening disease at the time of diagnosis were treated with an anthracycline-based combination chemotherapy regimen. When compared with those who received prednisone therapy, patients treated with combination chemotherapy had superior CR rates (64 versus 29 percent, respectively) and a longer median survival (19 versus 11 months, respectively).",
"     </li>",
"     <li>",
"      An analysis of 28 patients with AITL enrolled on prospective trials of CHOP or CHOP-like chemotherapy reported three-year event-free and overall survival rates of 50 and 68 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Retrospective studies have reported high survival rates with auto-HCT, especially for patients in first CR at the time of HCT. As an example, a retrospective trial of auto-HCT in 146 patients with AITL yielded two and four year OS rates of 67 and 59 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/35\">",
"       35",
"      </a>",
"      ]. When compared with those who had chemotherapy sensitive disease without a CR, patients who had achieved a CR prior to auto-HCT had superior rates of progression free survival (PFS) at two years (70 versus 42 percent) and four years (56 versus 30 percent). Patients who had refractory disease at the time of auto-HCT had the worst outcome with a PFS of 23 percent at 24 and 48 months.",
"     </li>",
"     <li>",
"      A retrospective analysis of 45 patients with AITL who underwent myeloablative (25 patients) or reduced intensity allogeneic HCT (allo-HCT) reported one- and three-year OS rates of 66 and 64 percent, respectively with 53 percent of patients being alive without disease progression at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/36\">",
"       36",
"      </a>",
"      ]. OS and PFS were significantly better for those patients with chemotherapy sensitive disease at the time of HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For medically fit patients with AITL, we suggest treatment with induction chemotherapy such as that used for PTCL, NOS (eg, CHOEP for patients under 60, CHOP for patients over 60) followed by auto-HCT for those patients who attain a CR. Those who can tolerate chemotherapy but are not candidates for auto-HCT can be treated with chemotherapy followed by observation. Patients who have comorbidities that prevent the use of combination chemotherapy may be considered for initial treatment with steroids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ). The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to chemotherapy cannot be recommended in this setting in the absence of trials demonstrating a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hepatosplenic T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the treatment of hepatosplenic T cell lymphoma. While up to half of patients may achieve a complete remission (CR) with chemotherapy, remissions are typically short lived with a median overall survival of approximately one year [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/38\">",
"     38",
"    </a>",
"    ]. No standard therapy exists, though autologous or even allogeneic transplantation should be considered in patients who achieve a CR. Although the data to support these aggressive strategies are limited, the outcome with chemotherapy alone is poor. Patients with severe thrombocytopenia may benefit from splenectomy prior to the initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Subcutaneous panniculitis-like T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous panniculitis-like T cell lymphoma is a very rare entity often presenting with an associated hemophagocytic syndrome (HPS). While previous classification systems included a gamma-delta variant, the current WHO classification system only recognizes those cases with a mature alpha beta T cell phenotype.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha beta &mdash; Patients with the",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      variant have more indolent disease confined to the subcutis, are less likely to have HPS, and have a favorable prognosis with a five-year overall survival rate of 82 percent (91 percent in the absence of HPS). Some of these patients can be managed like the more indolent cutaneous T cell lymphomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gamma delta &mdash; This entity has been renamed cutaneous",
"      <span class=\"nowrap\">",
"       gamma/delta",
"      </span>",
"      T cell lymphoma in the 2008 WHO classification. These patients are more likely to have HPS. The five-year overall survival rate is 11 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/40\">",
"       40",
"      </a>",
"      ]. These patients should be treated with aggressive, anthracycline-based chemotherapy with consideration of autologous or allogeneic stem cell transplantation if remission is achieved. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199074\">",
"    <span class=\"h2\">",
"     Extranodal NK/T cell lymphoma, nasal type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type is largely determined by the extent of disease. Localized disease is commonly treated with radiation therapy with or without chemotherapy while patients with advanced disease are treated with combination chemotherapy with or without hematopoietic cell transplantation. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=see_link\">",
"     \"Treatment of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Enteropathy-associated T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteropathy associated T cell lymphoma (EATL) is a rare condition that occurs most commonly in patients with gluten-sensitive enteropathy (celiac sprue). Treatment consists of combination chemotherapy used for other PTCLs. Patients who are candidates for autologous hematopoietic cell transplantation (HCT) may benefit from HCT in first remission. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Enteropathy-associated T cell intestinal lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H199031\">",
"    <span class=\"h2\">",
"     Adult T cell leukemia-lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia-lymphoma (ATL) is a peripheral T cell neoplasm associated with infection by the human T-lymphotropic virus, type I. Although it is considered one of the highly aggressive T cell non-Hodgkin lymphoma (NHL) variants, the disease course is variable and sometimes quite indolent.",
"   </p>",
"   <p>",
"    The treatment of ATL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"     \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). The post-treatment imaging study of choice is the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows for the distinction between active disease and fibrosis.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be obtained six to eight weeks after completion of chemotherapy and 12 weeks after the completion of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33065/abstract/1\">",
"     1",
"    </a>",
"    ]. A complete remission has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All post-treatment residual masses are negative on PET scan.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pretreatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the follow-up of patients with lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a partial remission is obtained, consolidation radiation therapy may be considered for patients with localized disease who are not candidates for transplantation. Otherwise, patients with a partial remission are frequently considered for second-line chemotherapy agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transplantation. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Consolidation therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every three months during the first two years, then every six months starting two years after complete response. Starting at year five, patients are seen once per year. At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH. We obtain a CT scan of the chest, abdomen, and pelvis every six months for the first three years then at year four and year five. We only obtain additional",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans to further evaluate any concerning findings noted on CT scans. We do not obtain routine CT scan after year five unless there are signs, symptoms, or exam findings to suggest relapse.",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults. There is no general consensus regarding the optimal treatment regimen for these patients and all patients should be encouraged to participate in clinical trials. We offer the following suggestions for patients who are not candidates for or choose not to participate in clinical trials.",
"   </p>",
"   <p>",
"    The treatment of the following subtypes of PTCL is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult T cell",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"       \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H20#H20\">",
"       \"Management of gastrointestinal lymphomas\", section on 'Enteropathy-associated T cell intestinal lymphoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mycosis",
"      <span class=\"nowrap\">",
"       fungoides/S&eacute;zary",
"      </span>",
"      syndrome &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"       \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type &mdash; (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=see_link\">",
"       \"Treatment of extranodal NK/T cell lymphoma, nasal type\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Induction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with newly diagnosed PTCL, we suggest induction combination chemotherapy with a CHOP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      )-based regimen rather than more intensive induction regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients younger than 60 years, we suggest the use of CHOP plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (CHOEP) rather than CHOP alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients over the age of 60 years, we suggest the use of CHOP without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Consolidation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the completion of induction chemotherapy, patients should be evaluated for the use of consolidation therapy with radiation therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autologous hematopoietic cell transplantation (HCT). Those with limited stage disease who achieve a partial response (PR) may attain a complete remission (CR) if consolidation radiation is administered. The use of auto-HCT in first CR is principally based upon the PTCL subtype and the International Prognostic Index (IPI) score (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with PTCL, NOS in first CR and a low or low intermediate IPI score, we suggest observation rather than auto-HCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Consolidation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with PTCL, NOS and a high intermediate or high IPI score, we suggest the use of auto-HCT in first CR rather than observation or allogeneic HCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Consolidation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ALK positive anaplastic large cell lymphoma (ALCL) who attain a CR, we suggest observation rather than auto-HCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Anaplastic large cell lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ALK negative ALCL, we suggest the use of consolidation auto-HCT in first CR, rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Anaplastic large cell lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with angioimmunoblastic T cell lymphoma (AITL), we suggest auto-HCT in first CR rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Those who can tolerate chemotherapy but are not candidates for auto-HCT can be treated with chemotherapy followed by observation. Patients who have comorbidities that prevent the use of combination chemotherapy may be considered for initial treatment with steroids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Angioimmunoblastic T cell lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/1\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/2\">",
"      Sonnen R, Schmidt WP, M&uuml;ller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005; 129:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/3\">",
"      Schmitz N, Tr&uuml;mper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116:3418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/4\">",
"      Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/5\">",
"      Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/6\">",
"      Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 2010; 151:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/7\">",
"      Escal&oacute;n MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005; 103:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/8\">",
"      Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/9\">",
"      Nakamura S, Shiota M, Nakagawa A, et al. Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 1997; 21:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/10\">",
"      Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/11\">",
"      Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93:3913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/12\">",
"      Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/13\">",
"      Rodr&iacute;guez J, Caballero MD, Guti&eacute;rrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/14\">",
"      Numata A, Miyamoto T, Ohno Y, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010; 45:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/15\">",
"      Hosing C, Champlin RE. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 2011; 22:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/16\">",
"      d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/17\">",
"      Reimer P, R&uuml;diger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/18\">",
"      Reimer P, Schertlin T, R&uuml;diger T, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5:304.",
"     </a>",
"    </li>",
"    <li>",
"     Reimer P, Ruediger T, Schertlin T, et al. Autologous stem cell transplantation as first line therapy in peripheral T cell lymphomas. Update of a prospective multicenter study [abstract]. Blood 2004; 104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/20\">",
"      Rodr&iacute;guez J, Conde E, Guti&eacute;rrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/21\">",
"      Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/22\">",
"      Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/23\">",
"      Rodr&iacute;guez J, Conde E, Guti&eacute;rrez A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007; 78:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/24\">",
"      Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003; 88:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/25\">",
"      Lee HK, Wilder RB, Jones D, et al. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. Leuk Lymphoma 2002; 43:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/26\">",
"      Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2008; 70:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/27\">",
"      Sakata K, Fuwa N, Kodaira T, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol 2006; 79:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/28\">",
"      Sandlund JT, Pui CH, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/29\">",
"      Deconinck E, Lamy T, Foussard C, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000; 109:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/30\">",
"      Fanin R, Silvestri F, Geromin A, et al. Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation. Blood 1996; 87:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/31\">",
"      Fanin R, Sperotto A, Silvestri F, et al. The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. Leuk Lymphoma 1999; 35:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/32\">",
"      Bordon V, De Paepe P, Dhooge C, et al. Successful treatment with allogeneic bone marrow transplantation of an early relapse of ALK-positive anaplastic large cell lymphoma. Haematologica 2005; 90:ECR19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/33\">",
"      Liso A, Tiacci E, Binazzi R, et al. Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. Lancet Oncol 2004; 5:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/34\">",
"      Siegert W, Agthe A, Griesser H, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992; 117:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/35\">",
"      Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/36\">",
"      Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/37\">",
"      Delfau-Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica 2012; 97:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/38\">",
"      Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009; 20:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/39\">",
"      Gumbs AA, Zain J, Neylon E, et al. Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia. Ann Surg Oncol 2009; 16:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/40\">",
"      Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33065/abstract/41\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4749 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33065=[""].join("\n");
var outline_f32_18_33065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONSOLIDATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Autologous",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Allogeneic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MODIFICATION FOR SUBTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Angioimmunoblastic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H199074\">",
"      Extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Enteropathy-associated T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H199031\">",
"      Adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Response assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Consolidation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2A\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2B\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 3\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/46/8942\" title=\"table 4\">",
"      CHOP-21",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/54/876\" title=\"table 5\">",
"      CHOP chemotherapy NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 6\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=related_link\">",
"      Treatment of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33066="Hematopoietic cell transplantation in chronic myeloid leukemia";
var content_f32_18_33066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation in chronic myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33066/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33066/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33066/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/18/33066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/18/33066/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/18/33066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome t(9;22)(q34;q11) resulting in the BCR-ABL fusion gene. This genetic abnormality results in the formation of a unique gene product (BCR-ABL), which is a constitutively active tyrosine kinase. It is this deregulated tyrosine kinase that is implicated in the development of CML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibitors of this tyrosine kinase, most notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , have been developed and used successfully to treat CML. Even with therapy, CML can progress from a relatively indolent disease (chronic stable phase) to a more aggressive disorder (accelerated phase), during which time disease control is more difficult to achieve. It can then culminate in an acute leukemia, termed \"blast crisis\", which is generally refractory to treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of CML with hematopoietic cell transplantation will be discussed here. Other treatments options are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in accelerated phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL TRANSPLANTATION ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the invariable progression of the disease, allogeneic hematopoietic cell transplantation (HCT) has been widely used. The results obtained with this modality are directly related to the phase of disease at the time of the transplant; among patients in chronic phase, transplantation within the first year results in the best outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The magnitude of these relationships was illustrated in a study in which allogeneic bone marrow transplantation (BMT) was performed in 62 patients in chronic phase, 26 in accelerated phase, and 27 in blast transformation (",
"    <a class=\"graphic graphic_figure graphicRef63246 \" href=\"UTD.htm?13/26/13742\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients transplanted in chronic phase had a higher actuarial survival at three years (58 versus 41 and 25 percent, respectively) and a lower actuarial rate of relapse (3 versus 12 and 27 percent).",
"     </li>",
"     <li>",
"      Patients transplanted within one year of diagnosis in chronic phase had a higher survival than those transplanted later (70 versus 40 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, decisions concerning the use of HCT have to be considered within the context of timing from the diagnosis of CML. By convention, the time of diagnosis is used as the beginning of the disease process, not the first development of symptoms, which often occurs much earlier.",
"   </p>",
"   <p>",
"    However, the decision concerning which treatment option to pursue in patients with CML has been greatly affected by the emergence of the tyrosine kinase inhibitors, which directly inhibit the mutant tyrosine kinase produced by the BCR-ABL fusion gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have also been advances in transplant techniques, which have resulted in reduced toxicities and improved outcomes, including pharmacologic monitoring of drug levels, non-myeloablative preparative regimens with reduced toxicity, and the availability of different sources of hematopoietic stem cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALLOGENEIC HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trials in the 1980s demonstrated that CML could be effectively treated with myeloablative chemoradiotherapy followed by syngeneic (identical twin) HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/4\">",
"     4",
"    </a>",
"    ]. A significant percentage of these patients achieved long-term remission and cure of their disease. However, the advantage of avoiding graft-versus-host disease (GVHD) with syngeneic transplantation was counterbalanced by an increased incidence of relapse, which was one of the initial observations leading to the concept of a graft-versus-leukemia (GVL) effect. In one series that compared the outcome of 103 syngeneic and 1030 HLA-matched sibling (allogeneic) transplants in patients with leukemia, the patients with CML who received a syngeneic transplant had a much higher three year rate of relapse (40 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using HLA-matched sibling donors, 50 to 75 percent of patients with CML transplanted in first or second chronic phase of their disease achieve long-term remissions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/1,3,6-8\">",
"     1,3,6-8",
"    </a>",
"    ]. The ability of allogeneic HCT to cure CML is related to the antileukemic effects of both the conditioning regimen and the GVL effect of the donor lymphocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of prognostic factors for predicting outcome after allogeneic HCT have been evaluated. The European Group for Blood and Marrow Transplantation (EGBMT) devised a risk score based on five separate characteristics, which predicted treatment-related mortality and five-year overall survival following allogeneic HCT (",
"    <a class=\"graphic graphic_table graphicRef67260 \" href=\"UTD.htm?35/31/36348\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/9\">",
"     9",
"    </a>",
"    ]. The EGBMT risk score was later validated using separate data from the International Bone Marrow Transplant Registry [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/10\">",
"     10",
"    </a>",
"    ]. The hematopoietic cell transplantation comorbidity index (HCT-CI) incorporates information on patient comorbidities and was designed to predict outcomes in patients undergoing allogeneic HCT for a variety of diseases (",
"    <a class=\"graphic graphic_table graphicRef59272 \" href=\"UTD.htm?7/48/7950\">",
"     table 2",
"    </a>",
"    ). Using this score, one study found that patients with comorbidities (HCT-CI &gt;0) and elevated levels of C-reactive protein had significantly higher rates of non-relapse mortality and lower overall survival at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/11\">",
"     11",
"    </a>",
"    ]. The Sokal and Hasford scores do not predict survival the setting of HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Disease phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important prognostic factor for survival following allogeneic HCT for CML is, as mentioned above, disease phase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/1,3,6,12-14\">",
"     1,3,6,12-14",
"    </a>",
"    ]. Disease-free survival (DFS) falls to 30 to 40 percent in patients in accelerated phase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/3,12\">",
"     3,12",
"    </a>",
"    ] and to 5 to 15 percent of patients in blastic phase (",
"    <a class=\"graphic graphic_figure graphicRef63246 \" href=\"UTD.htm?13/26/13742\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients in blast phase, giving chemotherapy or a tyrosine kinase inhibitor (TKI) prior to transplant to achieve a second chronic phase may be preferable to transplanting the patient in blast phase. In one study of 20 patients with CML in blast crisis, eight of 10 patients achieved second chronic phase after treatment with FLAN (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , cytosine arabinoside,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/15\">",
"     15",
"    </a>",
"    ]. Of the seven patients subsequently transplanted while in second chronic phase, four achieved continuing molecular remission. Median survival following transplantation for the entire group of 20 was 23 months; of the 10 patients transplanted in blast phase without prior chemotherapy, all died from leukemia, with median survival following transplantation of six months.",
"   </p>",
"   <p>",
"    An alternative, often preferable, option is the use of a TKI in an attempt to control the blast phase prior to transplantation. This is especially true in patients with myeloid blast crisis, which is generally refractory to chemotherapy. The 10 to 15 percent of patients with lymphoid blast crisis may benefit from chemotherapy including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in addition to TKIs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Accelerated or blast phase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     &nbsp;Disease duration",
"    </strong>",
"    &mdash; Another prognostic factor for improved outcomes is transplantation within the first year after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/1-3,13\">",
"     1-3,13",
"    </a>",
"    ]. This benefit is due at least in part to the negative impact of prior exposure to chemotherapy, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. It is recommended that any patient who is a candidate for HCT receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    rather than busulfan, if chemotherapy is required. Cumulative doses of busulfan of over 100 mg resulted in higher transplant related mortality, mainly due to pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Younger age may also improve survival after allogeneic HCT in CML [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. In the subgroup of patients under age 50, including children, who undergo this procedure during the first year of diagnosis, 70 to 80 percent will be alive and free of disease three to five years later [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/8,16,17\">",
"     8,16,17",
"    </a>",
"    ]. However, selected elderly patients (ie, &gt;60 years of age) have successfully undergone allogeneic HCT for CML with myeloablative preparative regimens, although treatment related mortality has been high [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of nonmyeloablative regimens with reduced toxicity has permitted even older patients to be transplanted (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Nonmyeloablative or reduce intensity HCT'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenomegaly, which is present in the majority of patients with CML, does",
"    <strong>",
"     not",
"    </strong>",
"    appear to affect the outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. However, patients with massive splenomegaly may have refractory cytopenias following transplantation, and such patients may benefit from low-dose splenic irradiation or even splenectomy prior to transplantation. In many cases, low doses of radiation dramatically reduce splenic size, symptoms of hypersplenism, and splenic sequestration of red blood cells and platelets following transplantation. Neither splenectomy nor splenic irradiation appears to have an effect on outcome, and should not be routinely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Preparative regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible importance of the preparative regimen for HCT was evaluated in randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    <span class=\"nowrap\">",
"     (BU/CY)",
"    </span>",
"    to fractionated total body irradiation and cyclophosphamide (FTBI-CY) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/16,21\">",
"     16,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .) No difference was noted in disease-free or overall survival; one study but not the other found a decreased risk of relapse in",
"    <span class=\"nowrap\">",
"     BU/CY",
"    </span>",
"    treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients treated with",
"    <span class=\"nowrap\">",
"     BU/CY,",
"    </span>",
"    those with steady-state plasma BU concentrations below 917",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    had a lower estimated three-year overall survival than those with steady-state concentrations above this level (64 versus 82 percent, p = 0.33), although the study was not sufficiently powered to detect this difference [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in a later study of 131 consecutive patients with CML treated with a",
"    <span class=\"nowrap\">",
"     BU/CY",
"    </span>",
"    regimen in which the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    dose was targeted to achieve a steady-state plasma concentration of &ge;900",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    estimated three-year post-transplant overall survival was 86 percent, with most patients being in molecular remission [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/23\">",
"     23",
"    </a>",
"    ]. As such, the use of intravenous busulfan and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    with pharmacokinetic monitoring of busulfan levels has emerged as an excellent preparative regimen for CML patients.",
"   </p>",
"   <p>",
"    One study attempted to define the optimal irradiation regimen prior to allogeneic transplantation in 116 patients with CML [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/24\">",
"     24",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (120",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    were used for prophylaxis against acute GVHD. The patients were randomized to receive 2.0 Gy fractions of irradiation daily for six days or a higher dose of 2.25 Gy fractions daily for seven days. The higher dose regimen resulted in a lower rate of relapse but no improvement in overall survival because of increased mortality from other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk assessment after first relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for survival following a first relapse after allogeneic hematopoietic cell transplantation were evaluated in 500 patients in the European Group for Blood and Marrow Transplantation registry. The following adverse factors were found on regression analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accelerated or blast phase at relapse (relative risk, RR: 3.1)",
"     </li>",
"     <li>",
"      Time from transplant to relapse &lt;1 year (RR: 2.3)",
"     </li>",
"     <li>",
"      Disease phase at transplant other than first chronic phase (RR: 2.0)",
"     </li>",
"     <li>",
"      Donor other than an HLA-identical sibling (RR: 1.6)",
"     </li>",
"     <li>",
"      Time from diagnosis to transplant &ge;2 years (RR: 1.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of individual adverse risk factors were cumulative: the probability of survival at 10 years after relapse was 42, 32, 14, 3, and zero percent for patients with no, 1, 2, 3, or 4 to 5 adverse risk factors, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding studies have documented the excellent long-term control of CML that can be achieved with allogeneic transplantation (all-HCT), particularly in patients under the age of 50 who are transplanted in chronic phase within one year of diagnosis. However, as with all allogeneic transplants, there is considerable up-front risk due to toxicity, infection, sinusoidal obstructive disease, and graft-versus-host disease (GVHD). Mortality risk in the first 100 days following transplantation is in the range of 10 to 20 percent for ideal transplant candidates with fully HLA-matched sibling donors; comorbid conditions increase this risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Survivors of HCT have a higher prevalence of long-term health-related complications. However, significant morbidity is uncommon; chronic graft versus host disease is the most important predictor of adverse medical late effects and poor overall health [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=see_link\">",
"     \"Quality of life following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest study to evaluate the long term effects of HCT in patients with CML included 2444 patients who underwent myeloablative allo-HCT for in first chronic phase prior to 1998 and survived in continuous complete remission for at least five years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/27\">",
"     27",
"    </a>",
"    ]. At a median follow-up of 11 years (range 5 to 25 years), the following were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall survival rates at 15 years after HCT from a sibling or unrelated donor were 88 and 87 percent, respectively.",
"     </li>",
"     <li>",
"      The cumulative incidence of relapse at 15 years for the same groups were 8 and 2 percent, respectively. The latest relapse was reported at 18 years after allo-HCT.",
"     </li>",
"     <li>",
"      Chronic GVHD increased non-relapse and overall mortality rates, but reduced the risk of relapse.",
"     </li>",
"     <li>",
"      Once patients reached 15 years post allo-HCT, mortality rates were similar to those of age, race, and sex-matched normal populations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparison to medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy with tyrosine kinase inhibitors (TKIs) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    has emerged as the preferred initial therapy for CML primarily because it lacks the up-front risk of HCT and is able to provide good disease control in the majority of patients. With the completion of randomized trials showing clear superiority of imatinib over interferon-alpha, use of the latter has largely been abandoned.",
"   </p>",
"   <p>",
"    Treatment with a TKI is preferred by the majority of patients due to the low risk of side effects and excellent response rates. However, the majority of patients still have detectable disease using sensitive PCR-based techniques. Therefore, careful monitoring is required in patients who would otherwise be candidates for allogeneic HCT. There are no trials comparing TKIs to allogeneic HCT in patients who would otherwise be candidates for transplantation. In addition the impact of prior treatment with a TKI on HCT outcomes is thought to be minimal, although information on this point is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general approach to patients treated with a TKI is to assess response at 3, 6, 12 and 18 months. Patients who do not achieve a complete hematological response within 3 months, some cytogenetic response by 6 months, at least a partial cytogenetic response by 12, and a complete cytogenetic response by 18 months should be considered for alternative approaches, such as allogeneic HCT or another TKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach to monitoring of CML patients includes the use of quantitative PCR. Achievement of at least a 3 log reduction in",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    transcript level has been associated with improved outcome. The level of",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    mRNA at 12 months of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    has been a predictive marker for progression-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/29\">",
"     29",
"    </a>",
"    ]. In another study, patients who achieved a 2 log or greater reduction in",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    transcripts either at the time of complete cytogenetic response or a greater than 3 log reduction at any time of treatment resulted in improved progression free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients who do not achieve these landmarks or have a rising transcript level should be strongly considered for alternative therapies, including allogeneic HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nonmyeloablative or reduce intensity HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloablative allogeneic HCT offers potential cure to patients with CML, but is associated with a high treatment-related mortality rate in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/18\">",
"     18",
"    </a>",
"    ]. Various reduced intensity (RIC) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/31\">",
"     31",
"    </a>",
"    ] or nonmyeloablative (NMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/32\">",
"     32",
"    </a>",
"    ] HCT regimens have been employed in fit older adults. However, the comparable efficacy of this approach remains to be proven. Additional information on nonmyeloablative and reduced intensity regimens is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NMA conditioning and RIC are allogeneic transplantation methods in which a less intensive preparative regimen is used in order to permit transplantation in selected patients who would not ordinarily be candidates for HCT with an attendant decrease in regimen-related toxicity and treatment-related mortality. What constitutes a NMA or RIC regimen has been loosely defined, but full agreement regarding these definitions has not been reached. In general, a NMA regimen will cause minimal cytopenia by itself and does not require stem cell support. In contrast, a RIC regimen will cause cytopenias, which may be prolonged and result in significant morbidity and mortality, and require hematopoietic stem cell support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H2#H2\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Preparative regimen intensity defined'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of RIC and NMA regimens may be particularly useful in patients &gt;50 years of age or those with other comorbid medical conditions. These approaches rely more on donor cellular immune effects (graft-versus-leukemia effect) and less on the cytotoxic effects of the preparative regimen to control the underlying disease (",
"    <a class=\"graphic graphic_figure graphicRef75962 \" href=\"UTD.htm?13/23/13694\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/33\">",
"     33",
"    </a>",
"    ]. If necessary, donor lymphocyte infusions (DLI) can be added to control the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Several different RIC and NMA regimens have been developed, varying in intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Specific NMA and RIC preparative regimens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the initial trials of RIC and NMA regimens in CML were performed before the widespread use of tyrosine kinase inhibitors. As such, many of the patients included in these trials were in first chronic phase. The following is a survey of publications that have reported outcomes with these regimens in CML [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/35,38-45\">",
"     35,38-45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-series reported the outcomes of 24 patients with CML in first chronic phase who underwent NMA HCT using a preparative regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , and antithymocyte globulin (ATG) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/40\">",
"       40",
"      </a>",
"      ]. At a median follow-up of 42 months, 21 of the 24 were alive and disease-free. The incidence of acute graft-versus-host disease was 54 percent initially, but increased when low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      was withdrawn.",
"     </li>",
"     <li>",
"      A non-randomized prospective trial of the same regimen in 186 patients with CML (64 percent in first chronic phase) reported three-year overall survival rates of 58 percent, with a 23 percent transplant-related mortality at 2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another analysis included 64 patients with advanced-phase CML (80 percent beyond first chronic phase) who were not eligible for myeloablative preparative regimens due to age or co-morbid conditions and were enrolled in four prospective trials [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/46\">",
"       46",
"      </a>",
"      ]. Low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      -based or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      -based regimens were used for conditioning and donor lymphocyte infusions were administered to patients without graft-versus-host disease. At a median follow-up of seven years, the following were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rates of five-year overall and progression-free survival were 33 and 20 percent, respectively. Five-year overall survival rates were higher for patients with chronic phase disease (48 versus 19 percent) when compared with those with accelerated or blast phase disease.",
"     </li>",
"     <li>",
"      Incidence of treatment-related mortality was 33, 39, and 48 percent at 100 days, 2 years, and 5 years, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective non-randomized trial evaluated the use of 6 to 12 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      followed by RIC HCT (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      as the conditioning regimen) and subsequent donor lymphocyte infusions in 18 patients with CML in first chronic phase with matched sibling donors [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/35\">",
"       35",
"      </a>",
"      ]. Of the 18 patients enrolled, 15 achieved a major cytogenetic response to imatinib and underwent transplant. Thirteen of these required donor lymphocyte infusions for disease control and four required a short course of imatinib after transplant. At a median follow-up of 31 months, all 15 patients were no longer taking imatinib. HCT was associated with significant morbidity including cytomegalovirus reactivation in 86 percent of patients at risk and Epstein-Barr virus positive post-transplantation lymphoproliferative disorder in two patients.",
"     </li>",
"     <li>",
"      The CIBMTR performed a retrospective analysis of 306 adults over age 40 years who underwent RIC (78 percent) or NMA conditioning followed by allogeneic HCT from an HLA-identical sibling (56 percent) or unrelated donor [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/45\">",
"       45",
"      </a>",
"      ]. The majority of patients had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      before HCT (74 percent) and approximately half (52 percent) were in first chronic phase. Cumulative transplant-related mortality at one year ranged from 13 to 18 percent across age groups. At a median of 48 months from HCT, rates of overall survival at three years were 41 to 54 percent. In multivariate analysis, survival was primarily affected by disease stage at the time of HCT and the use of imatinib before HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     T cell depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major obstacles to a successful outcome in allogeneic transplantation for CML, as in other diseases, are GVHD and infection. An alternative approach to the use of immunosuppressive drugs for the prevention of GVHD is T cell depletion. A variety of different T cell depletion techniques have been used; they generally result in less GVHD, but a higher risk of leukemic relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. One retrospective survey, for example, compared 46 patients who underwent allogeneic BMT with T cell depleted marrow to 40 patients who received non-T cell depleted marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/49\">",
"     49",
"    </a>",
"    ]. The T cell depleted group had significantly lower rates of grade 2 to 4 acute GVHD (15 versus 37 percent) and chronic GVHD (18 versus 42 percent), but a higher three-year probability of cytogenetic or hematologic relapse (62 versus 24 percent). Estimated three-year overall survival was similar in the two groups (72 versus 68 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=see_link\">",
"     \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternative strategy has been to perform a T cell depleted transplant to reduce GVHD followed by donor leukocyte infusion (DLI) to prevent leukemic relapse. In the above study, DLI led to complete remission in 17 of 20 such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/49\">",
"     49",
"    </a>",
"    ]. In three other reports of patients treated with a T cell depleted transplant followed by DLI at the time of relapse, estimated three- to five-year survivals were 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. (see",
"    <a class=\"local\" href=\"#H20\">",
"     'MRD and relapse after allo-HCT'",
"    </a>",
"    below)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     UNRELATED DONOR HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without HLA-matched sibling donors, matched unrelated donor (URD) hematopoietic cell transplantation is an acceptable alternative. An important advance with this procedure has been the development of techniques that permit molecular typing. These techniques have demonstrated that only about 55 percent of patients who are serologically identical are highly matched by molecular typing; patients who receive transplants from molecularly matched donors have better outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the relatively indolent nature of CML, there is usually adequate time to perform a search for a matched unrelated donor, which may take up to three to six months, through the National Marrow Donor Program and other donor agencies. Such searches should be initiated as soon as possible, since the average time for donor searching until transplantation for subjects in first chronic phase was approximately 10 months in a National Marrow Donor Program study [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/54\">",
"     54",
"    </a>",
"    ]. More rapid searches are possible if warranted by the patient's condition.",
"   </p>",
"   <p>",
"    The outcome of URD transplantation for patients with CML in chronic phase was initially reported to be 35 to 40 percent, lower than that observed with matched sibling donors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. As with sibling donors, patients with more advanced disease fared worse. However, the outcome has improved with the advances in molecular donor-recipient typing, supportive care, GVHD prophylaxis, and infectious disease prevention, especially for cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/60\">",
"     60",
"    </a>",
"    ]. In a 1998 report of 196 patients, estimated five year survival was 74 percent in patients who were 50 years of age or younger and were transplanted within one year after diagnosis; this result is similar to that achieved with HLA-matched sibling donors (",
"    <a class=\"graphic graphic_figure graphicRef77968 \" href=\"UTD.htm?25/14/25838\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Clinically significant GVHD occurred in 35 percent and relapse in 10 percent. As in allogeneic HCT, the outcome was worse in patients over age 50 or in those transplanted more than one year after diagnosis.",
"   </p>",
"   <p>",
"    The National Marrow Donor Program (NMDP) experience with URD transplantation in 1423 patients with CML between 1988 and 1999 has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/54,63\">",
"     54,63",
"    </a>",
"    ]. In their retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/63\">",
"     63",
"    </a>",
"    ], the incidence of grade",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    GVHD was 33 percent (95% CI: 30-36 percent), with 60 percent (95% CI: 56-63 percent) developing chronic GVHD. The probability of DFS for the 914 patients transplanted in chronic phase was 43 percent at 3 years, with",
"    <strong>",
"     improved DFS",
"    </strong>",
"    for the following groups (p&le;0.002 for each) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transplantation in chronic phase",
"     </li>",
"     <li>",
"      Early transplantation (&le;12 months from diagnosis)",
"     </li>",
"     <li>",
"      CMV seronegative recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Younger recipients (&le;35 years of age)",
"     </li>",
"     <li>",
"      Grade 0-II acute GVHD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients under the age of 35 undergoing URD transplantation in first chronic phase with a serologically HLA-matched donor had an overall five-year DFS of approximately 65 percent, while recipients &gt;35 years of age with similar good prognosis features had a five-year DFS of 47 percent (",
"    <a class=\"graphic graphic_figure graphicRef77968 \" href=\"UTD.htm?25/14/25838\">",
"     figure 3",
"    </a>",
"    ). Patients transplanted in second chronic phase, accelerated phase, and especially blast crisis, fared worse.",
"   </p>",
"   <p>",
"    Starting in 1991, the NMDP began collecting information prospectively for a comparison of URD versus matched related sibling donor (MRD) transplantation in CML [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/54\">",
"     54",
"    </a>",
"    ]. When compared with MRD transplantation, URD transplantation was associated with a significantly increased risk of graft failure and acute GVHD and a poorer overall and disease-free survival. However, for subjects &lt;30 years of age undergoing transplantation within one year from diagnosis while in first chronic phase, differences in five-year disease free survival between MRD and URD transplantation were minimal (68 versus 61 percent). As noted in their retrospective analysis, results for URD were significantly worse than MRD when subjects were &gt;30 years of age, or were transplanted more than one year after diagnosis.",
"   </p>",
"   <p>",
"    The effect of HLA class II gene disparity was evaluated in a later study from the NMDP, which included 696 recipients of URD transplants serologically matched at the HLA-A and -B loci [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/64\">",
"     64",
"    </a>",
"    ]. Matching at the HLA-DRB1 locus correlated with significantly improved survival, while single-locus disparity at the HLA-DQ or HLA-DP loci was not associated with significantly poorer survival. Molecular typing at HLA class II alleles, but increasingly more common at all alleles, is being performed by most centers.",
"   </p>",
"   <p>",
"    Superior effectiveness of peripheral blood (PBPC) versus bone marrow (BMT) as a source of hematopoietic cells was shown in one retrospective non-randomized study of 91 patients with CML undergoing MUD transplantation while in first chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/65\">",
"     65",
"    </a>",
"    ]. However, randomized prospective trials will be required in this setting, due to the potentially increased risk of both acute and chronic GVHD. Such a trial has completed enrollment under the auspices of the BMT Clinical Trials Network.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER DONOR SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients without HLA-matched sibling or unrelated donors, other donor sources have been used. Among the options are haploidentical donors for patients with CML who are usually in the advanced stages of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] and umbilical cord blood [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Both options have merits and problems and should be utilized only for patients without an MRD or URD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PRETREATMENT WITH TYROSINE KINASE INHIBITORS OR INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether pretreatment of patients with tyrosine kinase inhibitors or interferon alpha affects the outcome following HCT. Although definitive data are lacking, it appears safe to use these agents for relatively short periods of time, pending identification of an appropriate donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date there is relatively little information regarding the outcome of patients who have been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    alone or imatinib followed by the use of other tyrosine kinase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ) prior to allogeneic HCT. Initial reports have not found adverse outcomes and suggest that there may be a benefit to tumor load reduction with a tyrosine kinase inhibitor (TKI) prior to HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/71-76\">",
"     71-76",
"    </a>",
"    ]. This is principally supported by two observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most important prognostic factor for survival following HCT for CML is the disease phase at the time of transplantation. Treatment with TKIs prior to HCT appears to be a key factor in the management of accelerated or blast phase disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of chronic myeloid leukemia in blast crisis\", section on 'Eligible for HCT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of chronic myeloid leukemia in accelerated phase\", section on 'Patients eligible for HCT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When compared with historical figures, transplant-related mortality (TRM) rates have decreased in studies that have allowed the use of TKIs prior to HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. While there are many factors that impact TRM, this outcome is at least reassuring that the use of TKIs prior to HCT has not resulted in increased TRM. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who delay transplantation to receive interferon alpha (IFNa) therapy have a worse outcome independent of the type of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A number of retrospective analyses have evaluated the use of IFNa prior to HCT, but no prospective, randomized trials are available. The following observations illustrate the range of findings [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/78-82\">",
"     78-82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 103 patients, administration of IFNa for more than 12 months was associated with a worse outcome after transplantation (compared with prolonged therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ), mainly due to an increased risk of infection and graft failure [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were noted in another report of 184 patients receiving matched unrelated donor transplants in chronic phase; treatment with IFNa for at least six months was associated with a worse outcome after transplantation (compared with a shorter duration of IFNa, or no IFNa), mainly due to increased GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A much larger study from the International Bone Marrow Transplant Registry evaluated 873 patients who received an HLA-identical sibling bone marrow transplant during chronic phase; the median duration of IFNa administration was only two months (range one to 39 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/80\">",
"       80",
"      </a>",
"      ]. There was no adverse effect from IFNa therapy compared with patients who received only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      . To the contrary, patients treated with IFNa had a lower risk of relapse after transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A brief course of IFNa, pending identification of an appropriate donor, does not appear to adversely affect HCT outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MRD AND RELAPSE AFTER ALLO-HCT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Detection by PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of the Philadelphia chromosome permits the sensitive detection of",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    transcripts by polymerase chain reaction (PCR), and thus the presence of minimal residual disease (MRD). A number of studies have addressed the question of whether relapse can be predicted with PCR prior to a hematologic or cytogenetic relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/83\">",
"     83",
"    </a>",
"    ]. Initial findings in relatively small series were conflicting, due at least in part to variations in the techniques used and the time points at which patients were sampled [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/84-88\">",
"     84-88",
"    </a>",
"    ]. Further evaluation of a larger number of patients found that the value of PCR positivity varied with time [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive results obtained at 6 to 12 months, especially if they were persistent, were highly predictive of eventual relapse (42 versus 3 percent in PCR negative patients, relative risk 26)",
"     </li>",
"     <li>",
"      In comparison, positive results obtained within the first six months of transplantation were not predictive of relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a follow-up study by the same investigators, 379 consecutive CML patients alive at 18 months post-transplant were studied [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/90\">",
"     90",
"    </a>",
"    ]. Ninety patients had at least one positive Bcr-Abl test. Relapse was seen in 14 and 1 percent of the Bcr-Abl positive and negative patients, respectively, with an unadjusted hazard ratio of relapse for Bcr-Abl positivity of 19 (95% CI: 5-68). Of the 73 Bcr-Abl positive patients who failed to relapse, 69 percent had only one positive test at a median of 24 copies per ug RNA. In contrast, the median positivity for those relapsing was &gt;40,000",
"    <span class=\"nowrap\">",
"     copies/ug.",
"    </span>",
"   </p>",
"   <p>",
"    Quantitative PCR (Q-PCR) is also informative, as a positive result at three to five months post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/91\">",
"     91",
"    </a>",
"    ], and an increasing",
"    <span class=\"nowrap\">",
"     Bcr/Abl",
"    </span>",
"    with time [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/90,92\">",
"     90,92",
"    </a>",
"    ] were both predictive of impending disease recurrence. Lineage-specific mixed chimerism, especially in the myeloid series, preceded cytogenetic relapse by 2 to 12 months and p190",
"    <span class=\"nowrap\">",
"     (Bcr/Abl)",
"    </span>",
"    positivity preceded cytogenetic relapse by 1 to 6 months, suggesting that these two testable variables were highly predictive of impending disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/93\">",
"     93",
"    </a>",
"    ]. Interestingly, a minority of patients in long-term remission after HCT may have detectable Bcr-Abl transcripts by PCR that do not reflect reappearance of the original leukemic clone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/94\">",
"     94",
"    </a>",
"    ]. In contrast, a Bcr-Abl transcript that increases over time is more suggestive of disease relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Serial studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients who undergo allogeneic HCT become PCR negative, to date there has not been a clear consensus on what to do with a PCR positive result [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/95\">",
"     95",
"    </a>",
"    ]. To that end, a long-term study of serial Q-PCR results following allogeneic HCT in 243 patients with CML is of great interest [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/96\">",
"     96",
"    </a>",
"    ]. In this study, four groups of patients were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative &mdash; 15 percent were classified as persistently negative by Q-PCR or had only a single low-level positive result.",
"     </li>",
"     <li>",
"      Fluctuating &mdash; 21 percent had more than one positive Q-PCR result during follow-up but never more than two consecutive positive results.",
"     </li>",
"     <li>",
"      Persistent &mdash; 11 percent had three or more consecutive positive Q-PCR results which never satisfied the authors' criteria for molecular relapse.",
"     </li>",
"     <li>",
"      Relapse &mdash; 53 percent satisfied Q-PCR, cytogenetic, or hematologic criteria for relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At a median follow-up of seven years, the probability of disease relapse was 2.7, 20.8, and 30 percent for those in the negative, fluctuating, or persistent categories, respectively.",
"   </p>",
"   <p>",
"    Given that CML may relapse as late as 15 years following HCT, these results suggest a need for ongoing serial Q-PCR monitoring in all patients with CML following allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/97\">",
"     97",
"    </a>",
"    ]. This will be especially important in order to assess patients for early intervention (eg, DLI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , or other kinase inhibitors) should results indicate an increasing risk for relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Detection by FISH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of relapse via routine G-band cytogenetic analysis (CG) was compared with fluorescence in situ hybridization (FISH) with long-term colcemid exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. The latter \"hypermetaphase\" FISH technique (HMF) allowed scoring of up to 1000 cells, yielding a greater sensitivity of detection, with a false positive rate of &lt;2 x 10",
"    <sup>",
"     -4",
"    </sup>",
"    . In a study of 51 patients who received allogeneic HCT for CML, 12 patients were initially positive by the HMF method and negative by CG. In seven of these 12 patients, significant numbers of Ph+ cells were detected &gt;3 months after HCT; all seven patients ultimately showed Ph+ cells by CG at a median interval of 101 days, followed by clinical relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment: donor lymphocyte infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who suffer a relapse of CML following allogeneic transplantation can be treated by obtaining donor leukocytes from the original donor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. These donor leukocyte infusions (DLIs) have been extremely effective and provide further direct evidence for a GVL effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\", section on 'Donor lymphocyte infusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series, for example, 11 such patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    and DLI [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/102\">",
"     102",
"    </a>",
"    ]. Six of eight with stable CML after relapse underwent complete remission as defined by molecular genetic techniques able to identify one leukemic cell among one million normal cells. Three patients with accelerated CML after relapse did not enter remission.",
"   </p>",
"   <p>",
"    Molecular remissions attained after DLI appear to be quite durable. In one report, the probability of durable remission at three years was 87 percent among patients with CML relapsing in chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/103\">",
"     103",
"    </a>",
"    ]. In a study of 66 consecutive patients with CML relapsing after allogeneic transplant, molecular remission was attained after DLI in 67 percent. Survival at three years post-DLI was 95 and 53 percent for those achieving or not achieving molecular remission, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DLI has been complicated by graft-versus-host disease in a substantial percentage of patients and in some instances graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Thus, the optimal dose and schedule of DLI continues to be explored. A retrospective study, involving 298 patients treated with DLI at 51 participating centers, indicated that a lower starting dose (&le;0.2 x 10(8) mononuclear",
"    <span class=\"nowrap\">",
"     cells/kg)",
"    </span>",
"    was associated with less GVHD, less myelosuppression, and less DLI-related mortality than higher doses, although subsequent dose escalation was often necessary in order to achieve a response [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An approach to DLI that we have taken based upon these findings is to treat patients initially with 10",
"    <sup>",
"     7",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    for those with cytogenetic or persistent molecular positive results. This dose has not been associated with significant GVHD risk. If no response is observed within 2 to 3 months then dose escalation of DLI to 3 x 10",
"    <sup>",
"     7",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    and eventually 10",
"    <sup>",
"     8",
"    </sup>",
"    T",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    can be pursued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not respond to DLI alone may respond to the addition of IFNa. Some groups routinely use both modalities in patients who relapse following HCT.",
"   </p>",
"   <p>",
"    A number of patients relapsing after allogeneic HCT have been brought into complete hematologic, complete cytogenetic, or complete molecular remission following use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. Longer follow-up has indicated that these responses can be quite durable [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/107\">",
"     107",
"    </a>",
"    ]. Of interest, the percent of patients achieving molecular remissions following this treatment seems to be higher than that achieved with imatinib prior to allogeneic HCT. As an example, in a study of 44 patients with evidence of recurrence following allogeneic HCT, 70 percent achieved a complete molecular response using doses of imatinib ranging from 400 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unclear whether the drug can be stopped once a molecular response has been achieved. However, in one retrospective study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    treatment alone resulted in a higher incidence of relapse and inferior leukemia-free survival than did the use of donor lymphocyte infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Aims of initial therapy and duration of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies suggest that there may be a role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    maintenance therapy after allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     AUTOLOGOUS HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation has been explored in a limited number of patients with CML. Registry data and single institution studies have suggested that patients who undergo autologous HCT while in chronic phase, but not accelerated or blast phase, may attain a prolonged chronic phase of their disease and possibly enjoy improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. However, these studies were retrospective and therefore subject to patient selection bias.",
"   </p>",
"   <p>",
"    There is also a concern about reinfusion of clonogenic tumor cells with the stem cell inoculum. In one study, sufficient numbers of Philadelphia chromosome positive leukemic cells remained in the infused marrow to contribute to relapse of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/113\">",
"     113",
"    </a>",
"    ]. In an attempt to minimize this problem, a variety of strategies have been employed in an effort to enrich for normal unaffected stem cells. These include in vitro culture [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/114\">",
"     114",
"    </a>",
"    ], cell selection by fluorescence activated cell sorting (FACS) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/115\">",
"     115",
"    </a>",
"    ], and collection of cells upon recovery from chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/116-119\">",
"     116-119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the last approach, high numbers of circulating Philadelphia chromosome-negative hematopoietic progenitor cells can be mobilized. As an example, in two series of patients with CML who underwent autologous transplantation using this approach, regenerating marrow cells were Philadelphia chromosome-negative in 53 and 34 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. In one of the studies, despite a significant prolongation in disease-free survival at 36 months for subjects receiving Ph-negative, rather than Ph-positive cells (54 versus 14 percent), overall survival at 36 months was similar in the two groups (68 versus 53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autologous transplantation also may serve as a platform for subsequent immunotherapeutic interventions to suppress CML progenitors. These include therapy with interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/119,120\">",
"     119,120",
"    </a>",
"    ], interleukin-2, autologous natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/121\">",
"     121",
"    </a>",
"    ], or CD3+CD56+ cytotoxic effector cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intensive chemotherapy followed by autologous transplantation was pursued in a large cohort of patients with CML who were not eligible for allogeneic HCT. In this analysis of 46 patients the median survival after autologous HCT was 7.5 years. Approximately 20 percent of patients were Ph negative 10 years after HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?32/18/33066/abstract/123\">",
"     123",
"    </a>",
"    ]. This approach has merit for selected CML patients who are unable or unwilling to pursue the other treatment options discussed. However, with the introduction of several different TKIs and advances in allogeneic HCT, autologous HCT is very rarely a viable option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of chronic myeloid leukemia (CML) continues to be complex and the optimal approach remains a source of considerable debate. This debate has intensified with the success of the tyrosine kinase inhibitors (TKIs) and the use of nonmyeloablative hematopoietic cell transplantation (HCT).",
"     </li>",
"     <li>",
"      Treatment decisions require extensive consultation between the patient and a physician highly knowledgeable about the different treatment options. Determining whether the patient has an HLA matched sibling or initiating an unrelated donor search is warranted early in the course of therapy to determine which options are available. Since only 25 percent of siblings will be HLA matched and it often takes 3 to 6 months to identify an unrelated donor, anticipating the next potential therapeutic intervention in CML patients is important.",
"     </li>",
"     <li>",
"      Allogeneic HCT remains the only treatment approach with curative intent. However, many patients choose not to pursue allogeneic HCT upfront and prefer instead to be treated with a TKI first due to the more favorable toxicity profile and safety. For those patients who would otherwise be an allogeneic HCT candidate, careful and frequent follow-up with serial evaluations by FISH or PCR is critical to define the response to TKIs and to determine when other options should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"       \"Overview of the treatment of chronic myeloid leukemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Monitoring disease status'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/1\">",
"      Goldman JM, Apperley JF, Jones L, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/2\">",
"      McGlave P. Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol 1990; 27:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/3\">",
"      Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/4\">",
"      Fefer A, Cheever MA, Greenberg PD, et al. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 1982; 306:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/5\">",
"      Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/6\">",
"      McGlave P, Arthur D, Haake R, et al. Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J Clin Oncol 1987; 5:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/7\">",
"      Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/8\">",
"      Snyder DS, Negrin RS, O'Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994; 84:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/9\">",
"      Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/10\">",
"      Passweg JR, Walker I, Sobocinski KA, et al. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/11\">",
"      Pavl�� J, Kew AK, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 2010; 115:4018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/12\">",
"      Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994; 84:4368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/13\">",
"      Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/14\">",
"      Bacigalupo A, Gualandi F, Van Lint MT, et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). Bone Marrow Transplant 1993; 12:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/15\">",
"      Visani G, Rosti G, Bandini G, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol 2000; 109:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/16\">",
"      Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/17\">",
"      Cwynarski K, Roberts IA, Iacobelli S, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003; 102:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/18\">",
"      Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/19\">",
"      Kalhs P, Schwarzinger I, Anderson G, et al. A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995; 86:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/20\">",
"      Gratwohl A, Hermans J, von Biezen A, et al. No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia: results of a prospective randomized study. Bone Marrow Transplant 1992; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/21\">",
"      Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/22\">",
"      Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89:3055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/23\">",
"      Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/24\">",
"      Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/25\">",
"      Guglielmi C, Arcese W, Hermans J, et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2000; 95:3328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/26\">",
"      Baker KS, Gurney JG, Ness KK, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. Blood 2004; 104:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/27\">",
"      Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010; 28:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/28\">",
"      Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008; 112:3500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/29\">",
"      Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/30\">",
"      Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006; 107:4250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/31\">",
"      Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/32\">",
"      Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/33\">",
"      Uzunel M, Mattsson J, Brune M, et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003; 101:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/34\">",
"      McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999; 5:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/35\">",
"      Heaney NB, Copland M, Stewart K, et al. Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood 2008; 111:5252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/36\">",
"      Kerbauy FR, Storb R, Hegenbart U, et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005; 19:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/37\">",
"      Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/38\">",
"      Raiola AM, Van Lint MT, Lamparelli T, et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000; 109:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/39\">",
"      Bornh&auml;user M, Kiehl M, Siegert W, et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol 2001; 115:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/40\">",
"      Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/41\">",
"      Storb R, Yu C, Zaucha JM, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999; 94:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/42\">",
"      Weisser M, Schleuning M, Ledderose G, et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant 2004; 34:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/43\">",
"      Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/44\">",
"      Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/45\">",
"      Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012; 119:4083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/46\">",
"      Kebriaei P, Detry MA, Giralt S, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110:3456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/47\">",
"      Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/48\">",
"      Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/49\">",
"      Sehn LH, Alyea EP, Weller E, et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol 1999; 17:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/50\">",
"      Marks DI, Hughes TP, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol 1992; 81:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/51\">",
"      Elmaagacli AH, Peceny R, Steckel N, et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003; 101:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/52\">",
"      Drobyski WR, Hessner MJ, Klein JP, et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 1999; 94:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/53\">",
"      Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006; 107:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/54\">",
"      Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/55\">",
"      Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/56\">",
"      Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/57\">",
"      McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/58\">",
"      Gamis AS, Haake R, McGlave P, Ramsay NK. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol 1993; 11:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/59\">",
"      Arora M, Weisdorf DJ, Spellman SR, et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009; 27:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/60\">",
"      Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 112:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/61\">",
"      Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/62\">",
"      Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001; 110:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/63\">",
"      McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/64\">",
"      Petersdorf EW, Kollman C, Hurley CK, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 2001; 98:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/65\">",
"      Elmaagacli AH, Basoglu S, Peceny R, et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/66\">",
"      Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/67\">",
"      Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89:3864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/68\">",
"      Bogdani�� V, Nemet D, Kastelan A, et al. Umbilical cord blood transplantation in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Transplantation 1993; 56:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/69\">",
"      Laporte JP, Gorin NC, Rubinstein P, et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med 1996; 335:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/70\">",
"      Cornetta K, Laughlin M, Carter S, et al. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant 2005; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/71\">",
"      Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/72\">",
"      Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/73\">",
"      Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007; 110:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/74\">",
"      Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/75\">",
"      Menzel H, von Bubnoff N, Hochhaus A, et al. Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone Marrow Transplant 2007; 40:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/76\">",
"      Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/77\">",
"      Holowiecki J, Giebel S, Wojnar J, et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol 2008; 142:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/78\">",
"      Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/79\">",
"      Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/80\">",
"      Giralt S, Szydlo R, Goldman JM, et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood 2000; 95:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/81\">",
"      Lee SJ, Klein JP, Anasetti C, et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001; 98:3205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/82\">",
"      Pigneux A, Tanguy ML, Michallet M, et al. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol 2002; 116:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/83\">",
"      Mughal TI, Yong A, Szydlo RM, et al. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001; 115:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/84\">",
"      Gabert J, Thuret I, Lafage M, et al. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation. Lancet 1989; 2:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/85\">",
"      Sawyers CL, Timson L, Kawasaki ES, et al. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci U S A 1990; 87:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/86\">",
"      Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/87\">",
"      Delage R, Soiffer RJ, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991; 78:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/88\">",
"      Roth MS, Antin JH, Ash R, et al. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992; 79:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/89\">",
"      Radich JP, Gehly G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/90\">",
"      Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients \"late,\" 18 months or more after transplantation. Blood 2001; 98:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/91\">",
"      Olavarria E, Kanfer E, Szydlo R, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/92\">",
"      Lin F, van Rhee F, Goldman JM, Cross NC. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87:4473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/93\">",
"      Serrano J, Roman J, Sanchez J, et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood 2000; 95:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/94\">",
"      Sobrinho-Sim&otilde;es M, Wilczek V, Score J, et al. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010; 116:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/95\">",
"      Faderl S, Talpaz M, Kantarjian HM, Estrov Z. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood 1999; 93:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/96\">",
"      Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 2006; 107:4171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/97\">",
"      Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/98\">",
"      Maziarz RT. Transplantation for CML: lifelong PCR monitoring?. Blood 2006; 107:3820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/99\">",
"      Seong CM, Giralt S, Kantarjian H, et al. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol 2000; 18:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/100\">",
"      Bu&ntilde;o I, Moreno-Lopez E, Diez-Martin JL. Sequential fluorescence in situ hybridization for the quantification of minimal residual disease in recipient cells after sex-mismatched allogeneic stem cell transplantation. Br J Haematol 2002; 118:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/101\">",
"      Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/102\">",
"      Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/103\">",
"      Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/104\">",
"      Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/105\">",
"      Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/106\">",
"      Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/107\">",
"      DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10:5065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/108\">",
"      Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23:7583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/109\">",
"      Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/110\">",
"      Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110:4614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/111\">",
"      McGlave PB, De Fabritiis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994; 343:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/112\">",
"      Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia. Br J Haematol 1994; 86:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/113\">",
"      Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83:3068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/114\">",
"      Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/115\">",
"      Verfaillie CM, Miller WJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/116\">",
"      Carella AM, Chimirri F, Podest&agrave; M, et al. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1996; 17:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/117\">",
"      Verfaillie CM, Bhatia R, Steinbuch M, et al. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells. Blood 1998; 92:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/118\">",
"      Carella AM, Lerma E, Corsetti MT, et al. Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/119\">",
"      Koziner B, Dengra C, Lucero G, et al. Autologous stem cell transplantation for patients with chronic myeloid leukemia. The Argentine Group of Bone Marrow Transplantation (GATMO) experience. Cancer 2002; 95:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/120\">",
"      Olavarria E, Reiffers J, Boque C, et al. The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 2002; 118:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/121\">",
"      Cervantes F, Pierson BA, McGlave PB, et al. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood 1996; 87:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/122\">",
"      Hoyle C, Bangs CD, Chang P, et al. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92:3318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/18/33066/abstract/123\">",
"      Simonsson B, Oberg G, Bjoreman M, et al. Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up. Acta Haematol 2005; 113:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4494 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33066=[""].join("\n");
var outline_f32_18_33066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL TRANSPLANTATION ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALLOGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Disease phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Preparative regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk assessment after first relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparison to medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nonmyeloablative or reduce intensity HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      UNRELATED DONOR HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER DONOR SOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRETREATMENT WITH TYROSINE KINASE INHIBITORS OR INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MRD AND RELAPSE AFTER ALLO-HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Detection by PCR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Serial studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Detection by FISH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment: donor lymphocyte infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other treatment options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      AUTOLOGOUS HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4494|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/26/13742\" title=\"figure 1\">",
"      Transpl survival CML by stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/23/13694\" title=\"figure 2\">",
"      Graft versus leukemia in CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/14/25838\" title=\"figure 3\">",
"      Survival MUD transplant CML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/31/36348\" title=\"table 1\">",
"      Risk score CML transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/48/7950\" title=\"table 2\">",
"      HCT-CI and CCI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25529?source=related_link\">",
"      Quality of life following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27976?source=related_link\">",
"      Treatment of chronic myeloid leukemia in accelerated phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_18_33067="Classification of tremor";
var content_f32_18_33067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of tremor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tremor type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rest tremor",
"       </td>",
"       <td>",
"        Occurs in a body part that is supported in such a way that skeletal muscle activation is neither necessary nor intended.",
"       </td>",
"       <td>",
"        The patient is recumbent on a bed or seated on a couch with the body part supported. Tremor is often",
"enhanced by the performance of cognitive tasks or motor tasks with",
"other body parts, and it is often suppressed, at least temporarily, by",
"voluntary muscle contraction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postural tremor",
"       </td>",
"       <td>",
"        Occurs in an attempt to hold a body part motionless against the force of gravity.",
"       </td>",
"       <td>",
"        Extending the upper limbs horizontally, pointing at objects, sitting erect without support for the upper body, protruding the tongue.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Action tremor (including kinetic and isometric tremor)",
"       </td>",
"       <td>",
"        Occurs during any voluntary contraction of skeletal muscle. Isometric tremor occurs during a muscle contraction against a rigid stationary object.",
"       </td>",
"       <td>",
"        Finger-to-nose testing, heel-to-shin testing, reaching,",
"writing, drawing, pouring water into a cup, eating with utensils,",
"speaking. With isometric tremor: pushing against a wall, flexing the",
"wrist against a table, making a fist.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elble RJ. Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000; 54(suppl 4):S2. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33067=[""].join("\n");
var outline_f32_18_33067=null;
var title_f32_18_33068="Hallucinogen classification";
var content_f32_18_33068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common names and classification of select hallucinogens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Common name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Active ingredient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2CB, \"Bromo\", \"Nexus\"",
"       </td>",
"       <td>",
"        4-bromo-2,5-dimethoxyphenethylamine",
"       </td>",
"       <td>",
"        Phenylethylamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2CT-7, \"Blue Mystic\"",
"       </td>",
"       <td>",
"        2,5-dimethoxy-4-N-propylthiophethylamine",
"       </td>",
"       <td>",
"        Phenylethylamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AMT",
"       </td>",
"       <td>",
"        &alpha;-methyltryptamine",
"       </td>",
"       <td>",
"        Indolealkylamine (tryptamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DMT,",
"        <em>",
"         Ayahuasca",
"        </em>",
"       </td>",
"       <td>",
"        Dimethyltryptamine",
"       </td>",
"       <td>",
"        Indolealkylamine (tryptamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dextromethorphan, DXM",
"       </td>",
"       <td>",
"        Dextromethorphan",
"       </td>",
"       <td>",
"        Arylcyclohexylamine (piperidine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Foxy Methoxy\"",
"       </td>",
"       <td>",
"        5-MeO-DIPT (5-methoxydimethyl tryptamine)",
"       </td>",
"       <td>",
"        Indolealkylamine (tryptamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawaiian baby woodrose (",
"        <em>",
"         Argyreia nervosa",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Ergine",
"       </td>",
"       <td>",
"        Lysergamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibogaine",
"       </td>",
"       <td>",
"        12-methoxybogamine",
"       </td>",
"       <td>",
"        Indolealkylamine (tryptamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketamine, \"Special K\"",
"       </td>",
"       <td>",
"        Ketamine",
"       </td>",
"       <td>",
"        Arylcyclohexylamine (piperidine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LSD",
"       </td>",
"       <td>",
"        D-lysergic acid diethylamide",
"       </td>",
"       <td>",
"        Lysergamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mescaline, peyote",
"       </td>",
"       <td>",
"        3,4,5-trimethoxy-phenethylamine",
"       </td>",
"       <td>",
"        Phenylethylamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morning glory (",
"        <em>",
"         Ipomoea violacea",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Lysergic acid hydroxyethylamide",
"       </td>",
"       <td>",
"        Lysergamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCP, \"Angel dust\"",
"       </td>",
"       <td>",
"        Phencyclidine",
"       </td>",
"       <td>",
"        Arylcyclohexylamine (piperidine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psilocybin, \"Magic mushroom\"",
"       </td>",
"       <td>",
"        Psilocin (N,N-dimethyl-4-phosphoryloxytryptamine)",
"       </td>",
"       <td>",
"        Indolealkylamine (tryptamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Salvia divinorum",
"        </em>",
"       </td>",
"       <td>",
"        Salvinorin A",
"       </td>",
"       <td>",
"        Diterpene alkaloid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33068=[""].join("\n");
var outline_f32_18_33068=null;
var title_f32_18_33069="Anticoag AF age risk factors";
var content_f32_18_33069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Benefit of anticoagulation in chronic atrial fibrillation is related to age and risk factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 158px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pooled data from the randomized controlled trials of warfarin or aspirin in atrial fibrillation show that the reduction in the stroke rate is associated with age and the presence (plus sign) or absence (minus sign) of at least one risk factor (history of hypertension, history of diabetes, previous transient ischemic attack, or heart failure). Among patients less than 65 years of age, warfarin reduced the rate of stroke only in those with risk factors, while the risk of stroke in those without risk factors was low with or without warfarin therapy. Among patients 65 to 75 years of age without risk factors, aspirin and warfarin were equally effective for stroke prevention, while in those with risk factors warfarin significantly reduced the incidence of stroke; aspirin has not been evaluated in this population. Among patients over 75 years of age without risk factors, warfarin is an effective therapy while aspirin has not been evaluated; in those with risk factors, warfarin, but not aspirin, is an effective therapy for stroke prevention.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ezekowitz MD, Levine JA. JAMA 1999; 99:1830.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33069=[""].join("\n");
var outline_f32_18_33069=null;
var title_f32_18_33070="Calcific aortic stenosis color doppler echocardiogram";
var content_f32_18_33070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/68228/aoscldop_conv.mp4?title=Calcific+aortic+stenosis+color+doppler+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcific aortic stenosis color doppler echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long axis view of color flow doppler showing echo dense calcified aortic valve and trace aortic regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33070=[""].join("\n");
var outline_f32_18_33070=null;
var title_f32_18_33071="Tetralogy Fallot PA angio II";
var content_f32_18_33071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Main pulmonary artery angiogram after stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following placement of a balloon expandable stent in the proximal left pulmonary artery (*) of a patient with tetralogy of Fallot there is significant improvement in size of the proximal left pulmonary artery (LPA).",
"    <div class=\"footnotes\">",
"     RPA: right pulmonary artery; RV: right ventricle; MPA: main pulmonary artery.",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Thomas Doyle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_18_33071=[""].join("\n");
var outline_f32_18_33071=null;
